Cyclosporin A (NSC 290193)

For research use only. Not for use in humans.

目录号：S2286 别名： Cyclosporine A, Cyclosporine, Ciclosporin, CsA 中文名称：环孢菌素A

Cyclosporin A (NSC 290193) Chemical Structure

CAS No. 59865-13-3

Cyclosporin A (NSC 290193, Cyclosporine A, Cyclosporine, Ciclosporin, CsA)是一种免疫抑制剂，与亲环素结合，随后抑制calcineurin，无细胞试验中IC50为7 nM，广泛用于预防器官移植反应中的排斥反应。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1073.15	现货
50mg	RMB 786.07	现货
200mg	RMB 1957.41	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Cyclosporin A (NSC 290193)发表文献50篇：

Cancer Cell, 2018, 33(3):480-494

PubMed: 29533786 ( click the link to review the publication )

Cell Rep, 2021, 35(7):109159

PubMed: 34010655 ( click the link to review the publication )

PLoS Biol, 2021, 19(4):e3001134

PubMed: 33901180 ( click the link to review the publication )

J Cell Mol Med, 2021, 25(12):5729-5743

PubMed: 33949118 ( click the link to review the publication )

Phytomedicine, 2021, 85:153551

PubMed: 33827043 ( click the link to review the publication )

Br J Nutr, 2021, 1-11

PubMed: 33663624 ( click the link to review the publication )

Peptides, 2021, S0196-9781(21)00117-0

PubMed: 34242679 ( click the link to review the publication )

Clin Transl Med, 2021, 11(4):e390

PubMed: 33931967 ( click the link to review the publication )

Mol Cell, 2021, S1097-2765(21)00087-3

PubMed: 33626321 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2021, 414:115426

PubMed: 33524445 ( click the link to review the publication )

Anal Chem, 2020, 10.1021/acs.analchem.0c02756

PubMed: 32933243 ( click the link to review the publication )

Free Radic Biol Med, 2020, 150:109-119

PubMed: 32105828 ( click the link to review the publication )

Toxicol In Vitro, 2020, 8;66:104857

PubMed: 32278034 ( click the link to review the publication )

J Fungi (Basel), 2020, 6(3):E103

PubMed: 32650564 ( click the link to review the publication )

Circulation, 2019, 10.1161/CIRCULATIONAHA.118.037227

PubMed: 31163979 ( click the link to review the publication )

J Clin Invest, 2019, 129(6):2431-2445

PubMed: 31081803 ( click the link to review the publication )

Autophagy, 2019, 15(3):493-509

PubMed: 30304977 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-19-1982

PubMed: 31582380 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):487

PubMed: 31822296 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2019, 14:192-203

PubMed: 30623853 ( click the link to review the publication )

Front Immunol, 2019, 10:2952

PubMed: 31921197 ( click the link to review the publication )

J Antimicrob Chemother, 2019, 74(7):1921-1927

PubMed: 30934052 ( click the link to review the publication )

Oxid Med Cell Longev, 2019, 2019:4248529

PubMed: 30881590 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(10):6897-6906

PubMed: 31379115 ( click the link to review the publication )
Front Microbiol, 2019,

PubMed: 32038504 ( click the link to review the publication )

J Med Virol, 2019, 91(8):1440-1447

PubMed: 30900754 ( click the link to review the publication )

Med Sci Monit, 2019,

PubMed: 30913205 ( click the link to review the publication )

Biochim Biophys Acta Gene Regul Mech, 2019, 1862(8):846-857

PubMed: 31054961 ( click the link to review the publication )

Nat Commun, 2018, 9(1):873

PubMed: 29491374 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

Oncogenesis, 2018, 7(11):91

PubMed: 30467308 ( click the link to review the publication )

Sci Rep, 2018, 8(1):10910

PubMed: 30026610 ( click the link to review the publication )

Chem Res Toxicol, 2018, 31(2):127-136

PubMed: 29156121 ( click the link to review the publication )

Sci Adv, 2018, 4(8):eaas9784

PubMed: 30101190 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(10):1274-1285

PubMed: 28892080 ( click the link to review the publication )

Elife, 2017, 6e26733

PubMed: 28737489 ( click the link to review the publication )

J Neurochem, 2017, 143(3):282-293

PubMed: 28902407 ( click the link to review the publication )

Int J Cardiol, 2017, 227:201-208

PubMed: 27839819 ( click the link to review the publication )

Am J Physiol Renal Physiol, 2017, 313(2):F404-F413

PubMed: 28381458 ( click the link to review the publication )

PLoS One, 2017, 12(10):e0187123

PubMed: 29073235 ( click the link to review the publication )

J Mol Neurosci, 2017, 61(2):267-278

PubMed: 28054226 ( click the link to review the publication )

Pharm Res, 2016, 33(2):395-403

PubMed: 26415646 ( click the link to review the publication )

Int J Mol Med, 2016, 37(3):631-8

PubMed: 26846204 ( click the link to review the publication )

J Virol Methods, 2016, 238:13-20

PubMed: 27678028 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6711-26

PubMed: 26744319 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.32

PubMed: 25728673 ( click the link to review the publication )

Antiviral Res, 2015, 120:140-6

PubMed: 26086883 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(3):318-22

PubMed: 24335466 ( click the link to review the publication )
Arch Environ Con Tox, 2014, 68(1):31-7

PubMed: 25194241 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1833(3):652-62

PubMed: 23228564 ( click the link to review the publication )

产品安全说明书

Antineoplastic and Immunosuppressive Antibiotics抑制剂选择性比较

生物活性

产品描述

靶点

calcineurin ^[1]
(Cell-free assay)

7 nM

体外研究

在T细胞中，Cyclosporin A与亲环蛋白(免疫亲和素)结合^[1]，形成亲环蛋白-Cyclosporin A复合体，其结合并抑制钙调磷酸酶。^[2]Cyclosporin A 抑制钙调磷酸酶，IC50 是7 nM^[3]，随后阻断NF-AT核转运。 ^[4]Cyclosporin A通过抑制MTP(线粒体通透性转换孔)的开放而影响线粒体，IC50 是39 nM。^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
rat H42E cells	NH\xdI9EgXSxdH;4bYPDqGG\|c3H5			MYTDfZRwfG:6aXPpeJkh[WejaX7zeEBz[XRiSESySUBk\WyuczDhd5Nme3OnZDDhd{BqdnS{YXPlcIx2dGG{IFHUVEBt\X[nbDygWGM2OD12MjFOwG0>	NV;vNG9NRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm1NFIxPThpPkG5OVAzODV6PD;hQi=>
mouse L929 cells	Mkj6R5l1d3SxeHnjxsBie3OjeR?=		NIf0cGk{KGSjeYO=	MkK3R5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgUFkzQSClZXzsd{Bi\nSncjCzJIRigXNiYomgUXRUKGG\|c3H5MEBKSzVyPUOwJO69VQ>?	Mn2xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7OEWxPVUoRjJ3OUi1NVk2RC:jPh?=
human Huh-Mono cells	NFfq[HNEgXSxdH;4bYPDqGG\|c3H5		MUSzJIRigXN?	MlnQR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTJVpNU2xbn:gZ4VtdHNiYX\0[ZIhOyCmYYnzJIJ6KE2WVDDhd5Nige,:jDDDR\|UxRTJ2IN88US=>	NXfHXmtYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2NlU4PjZpPkG4OlI2PzZ4PD;hQi=>
MDCK cells	MYHDfZRwfG:6aXRCpIF{e2G7			NEOwR3FEgXSxdH;4bYNqfHliYXfhbY5{fCCPRFPLJINmdGy\|LDDUR\|UxRTlwOTFOwG0>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDJzMkGwNEc,OTh{MUKxNFA9N2F-
human LCC-6 cells	MX3DfZRwfG:6aXRCpIF{e2G7		MWO3NkBp	NYjHeHNYS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVEOFLU[gZ4VtdHNiYX\0[ZIhPzJiaILzMEBKSzVyPUiuN{DPxE1?	NYXtZm1kRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzNlA1ODJpPkKyN\|IxPDB{PD;hQi=>
human HeLa cells	MUjDfZRwfG:6aXRCpIF{e2G7			MXjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzMEBVSzVyPUiuN{DPxE1?	MojBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh{MUKxNFAoRjF6MkGyNVAxRC:jPh?=
african green monkey Vero cells	M365S2Z2dmO2aX;uJIF{e2G7		MkXnNlQhcA>?	MX\BcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDX[ZN1KE6rbHWgeolzfXNiaX7m[YN1\WRiaX6gZYZzcWOjbjDndoVmdiCvb37r[ZkhXmW{bzDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckB3cXKjbDDSUmEhe3mwdHjld4l{KGGodHXyJFI1KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFnDOVA:QCEQvF2=	NGj6fo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUS1NVI5Pid-MUm0OVEzQDZ:L3G+
human Huh-9-13 cells	NXHqcpVVS3m2b4TvfIlkyqCjc4PhfS=>		NH;DW2Q{KGSjeYO=	NUnMeVF2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUHWqLUmtNVMh[2WubIOgZYZ1\XJiMzDkZZl{KGK7IF3UWEBie3Ojef-8kEBESzVyPUeg{txO	M4CyelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkK1O\|Y3Lz5zOE[yOVc3PjxxYU6=
human HuH6 cells	MV\DfZRwfG:6aXRCpIF{e2G7		NHzqNGU{KGSjeYO=	NXTQ[ZRzS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUHWKNjDj[YxteyCjZoTldkA{KGSjeYOgZpkhVVSWIHHzd4F6NCCFQ{WwQVch\|ryP	M{nmN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkK1O\|Y3Lz5zOE[yOVc3PjxxYU6=
human Huh5-2 cells	MXXDfZRwfG:6aXRCpIF{e2G7		NYPxdnhkOyCmYYnz	Moe2R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTJVpPS1{IHPlcIx{KGGodHXyJFMh\GG7czDifUBOXFRiYYPzZZkhNCCFQ{WwQVYh\|ryP	M1zMRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkK1O\|Y3Lz5zOE[yOVc3PjxxYU6=
human HuH7 cells	NYLlPZJSS3m2b4TvfIlkyqCjc4PhfS=>			NFvkbJZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJfUh5IHPlcIx{KGG\|c3Xzd4VlKGG\|IILlcIVie2Vib3[gcIFkfGG2ZTDk[Yh6\HKxZ3XuZZNmNCCLQ{WwQVUvQDFizszN	M1;sZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOUSzN\|kxLz5{MEm0N\|M6ODxxYU6=
human 2008 cells	MY\GeY5kfGmxbjDhd5NigQ>?			MmnyTY5pcWKrdHnvckBw\iCqdX3hckBOWlBzIHnuJIh2dWGwIEKwNFgh[2WubIOsJGlEPTB;ND63PEDPxE1?	M1vXTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6N{C3PFg1Lz5zOEewO\|g5PDxxYU6=
human HeLa cells	M4S2O2Z2dmO2aX;uJIF{e2G7			Mn;RRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTHBXNTF6IHnu[oVkfGWmIHnuJIh2dWGwIFjlUIEh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjD2bZJidCC{ZYDsbYNifGmxbjDh[pRmeiB5IHThfZPwxIxiVFO1NF01NjZizszN	MnTrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh{MUKxNFAoRjF6MkGyNVAxRC:jPh?=
leukemia CEM cells	M2r1fGZ2dmO2aX;uJIF{e2G7			MUfJcohq[mm2b4L5JIFkfGm4aYT5JIFo[Wmwc4SgTJVu[W5iTVTSNUBRNUeueXPvdJJwfGWrbjDBRmMhXHKjboPwc5J1\XJidYPpcochdGW3a3XtbYEhS0WPIHPlcIx{NCCLQ{WwQVMvPCEQvF2=	M3\UfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{M{[xN\|g4Lz5zMkO2NVM5PzxxYU6=
human Caco2 cells	NGfUTWlHfW6ldHnvckBie3OjeR?=			M{DVW45pcWKrdHnvckBw\iCSLXfwJIlvKGi3bXHuJGNi[29{IHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBlcWexeHnuJIVn\my3eDygTWM2OD1{Lkmg{txO	NWPWbppwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPFI1PThpPkKzN\|gzPDV6PD;hQi=>
human MDA435/LCC6MDR cells	NWDqeodXS3m2b4TvfIlkyqCjc4PhfS=>		NYTvZnJbPzKq	M4XMW2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSTR\|NT;MR2M3VUSUIHPlcIx{KGW6cILld5NqdmdiTVTSJIFnfGW{IEeyJIhze+,:jDDJR\|UxRTJwODFOwG0>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN{MESwNkc,OjJ\|MkC0NFI9N2F-
guinea pig ventricular myocytes	MVjGeY5kfGmxbjDhd5NigQ>?			MXrJcohq[mm2aX;uJI9nKExvdInw[UBk[WylaYXtJINp[W6wZXygcYVie3W{ZXSgeZNqdmdid3jvcIUu[2WubDDwZZRkcCClbHHtdEBqdiCpdXnu[YEheGmpII\lcpRzcWO3bHHyJI16d2O7dHXzMEBKSzVyPUKg{txO	MmexQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5NkGwNFAoRjJ{N{[xNFAxRC:jPh?=
KB/MDR cell	NFLWUZNHfW6ldHnvckBie3OjeR?=		MlTxO\|IhcA>?	NV;S[\|hDUW6qaXLpeI9zgSCjY4Tpeol1gSCjZ3HpcpN1KEuEL13EVkBk\WyuIHzpcoUh[W[2ZYKgO\|IhcHJib3[g[JJ2\yCneIDvd5Vz\SxiSVO1NF0yNjVizszN	NESyW5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUS4NVk6OSd-MUW0PFE6QTF:L3G+
A2780/ADR cells	MmLPSpVv[3Srb36gZZN{[Xl?			NGT5d2tKdmirYnn0bY9vKG:oIGCt[4x6[2:ycn;0[YlvKGW6cILld5Nm\CCrbjDBNlc5OC:DRGKgZ4VtdHNiYomgZ4Ft[2WrbjDBUUBie3Ojef-8kEBKSzVyPUGuOFEzPTRizszN	NEm1e\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{i5NFA6PCd-MUe4PVAxQTR:L3G+
human K562/R7 cells	MVTGeY5kfGmxbjDhd5NigQ>?	MWWxJO69VQ>?	M4XSNVczKGh?	MnTPVI91\W62aXH0bY9vKG:oIHTvfI9zfWKrY3nuMYlv\HWlZXSgZ5l1d3SxeHnjbZR6KGGpYXnud5Qh\G:6b4L1ZolkcW5vcnXzbZN1[W62IHj1cYFvKEt3NkKvVlch[2WubIOgZZN{\XO\|ZXSgZZMh\G:6b4L1ZolkcW5iSVO1NEBifCBzIIXNJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTB;MD63JO69VQ>?	NGDPWJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[zOFA1OSd-MkW2N\|QxPDF:L3G+
LLC-PK1 epithelial cells	MojpSpVv[3Srb36gZZN{[Xl?			MkXwTY5pcWKrdHnvckBw\iCSLXfsfYNweHKxdHXpckwhdW:3c3WgUE1u\HJzYjDlfJBz\XO\|ZXSgbY4hVEyFLWDLNUBmeGm2aHXsbYFtKGOnbHzzJJV{cW6pIHPhcINmcW5vQV2gdI9t[XKrc3H0bY9vKGG\|c3H589yNKEmFNUC9NE44KM7:TR?=	M3Xsc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{Nkm5N\|g6Lz5zMk[5PVM5QTxxYU6=
mouse L5178 cells	NX\PTod6TnWwY4Tpc44h[XO\|YYm=		MmruNlAhdWmwcx?=	MYHJcohq[mm2aX;uJI9nKGi3bXHuJGFDS0JzLX3l[IlifGWmIILoc4RidWmwZTCxNlMh\W[obIX4JIlvKG2xdYPlJGw2OTd6IHPlcIx{KGW6cILld5NqdmdiaIXtZY4hVUSUMTDh[pRmeiB{MDDtbY5{KGK7IF\BR3Mh[W6jbInzbZMtKEmFNUC9NE43PSEQvF2=	M4LtZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{SxO\|Q2Lz5{MUO0NVc1PTxxYU6=
KB cell	M2DTbmZ2dmO2aX;uJIF{e2G7			NXLPb\|ZOUW6qaXLpeI9zgSCjY4Tpeol1gSCjZ3HpcpN1KEuEIHPlcIwhdGmwZTDh[pRmeiB5MjDoJI9nKGS{dXeg[Zhxd3O3cnWsJGlEPTB;MD62JO69VQ>?	NV3qTYlORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW0PFE6QTFpPkG1OFgyQTlzPD;hQi=>
mouse mammary carcinoma cell line EMT6/AR 1.0	MXjGeY5kfGmxbjDhd5NigQ>?			NVrPW4JZWmW4ZYLzZYwh\W[oZXP0JI9vKHSqZTDhZ4N2dXWuYYTpc44hd2ZiW{PIYU0h\GG3bn;yeYJq[2mwIHnuJI1wfXOnIH3hcY1ienliY3HyZ4lvd22jIHPlcIwhdGmwZTDFUXQ3N0GUIEGuNEwhUUN3ME2wMlQ1KM7:TR?=	NFHtZlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMEC5PFY4OSd-MUCwPVg3PzF:L3G+
CK1 cells	MWjGeY5kfGmxbjDhd5NigQ>?			M2DYNGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhRXi1\|MzDpcoZm[3SnZDDpckBEUzFiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB3cXKjbDDy[ZBtcWOjdHnvckBi\nSncjC3JIRigXNuIGTDOVA:OC5\|IN88US=>	NXXuTHpoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyNVIyODBpPkG4NlEzOTByPD;hQi=>
HEK293 cells	NHfwVmRHfW6ldHnvckBie3OjeR?=			MU\Jcohq[mm2aX;uJI9nKE:DVGCxRlEhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJIF{e2W\|c3XkJIF{KHC{b4TlbY4udWWmaXH0[YQheGm2YY\hd5RifGmwIIXweIFs\e,:jDDLbV0xNjJizszN	NHT6[4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkW4O\|k5Pid-MkK1PFc6QDZ:L3G+
human MDA435/LCC6MDR cells	M4DoRmZ2dmO2aX;uJIF{e2G7		M4nqPFUh\GG7cx?=	NU\kN3AzVW:mdXzheIlwdiCxZjDQMYdxKCi3bnvuc5dvKG:{aXfpckkhfHKjboPm[YN1\WRiaX6gbJVu[W5iTVTBOFM2N0yFQ{\NSHIh[2WubIOgZZN{\XO\|ZXSgZZMhemW4ZYLzbY5oKHCjY3zpeIF5\WxicnXzbZN1[W6lZTDt[YF{fXKnZDDhd{Bk\WyuIIP1dpZqfmGuIHHmeIVzKDViZHH5d{BjgSCPVGOgZZN{[XluIFXDOVA:OC5yM{Kg{txONg>?	NITWOZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm4OVE6PSd-MkW5PFUyQTV:L3G+
human PBMC	M3zFfHBzd2yrZnXyZZRqd25iYYPzZZk>			NETs[YxCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDCUWMtKEmFNUC9NVIhdk1?	M{X2NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3Nke5N\|A6Lz5zNU[3PVMxQTxxYU6=
mouse T cells	MWjGeY5kfGmxbjDhd5NigQ>?		NXPXSoVNPCCmYYnz	NGjUc2hKdW23bn;zeZBxemW\|c3n2[UBi[3Srdnn0fUBqdiCvb4Xz[UBVKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[geJdwKHejeTDtbZhm\CCueX3wbI9kgXSnIILlZYN1cW:wIHHmeIVzKDRiZHH5d{BjgSCPVGSgZZN{[XluIHnjOVA:OTFibl2=	MknYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7OES5PFcoRjJ{OUi0PVg4RC:jPh?=
human splenocytes	MlzVSpVv[3Srb36gZZN{[Xl?		NYrDN5JRPCCmYYnz	MnjtTY1ufW6xc4XwdJJme3OrdnWgZYN1cX[rdImgbY4hcHWvYX6gd5Bt\W6xY4n0[ZMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBcO0ifdHj5cYllcW6nIHnuZ49zeG:{YYTpc44h[W[2ZYKgOEBl[Xm\|IHL5JIFtdG:pZX7pZ{BucXinZDDsfY1xcG:leYTlJJJm[WO2aX;uJIF{e2G7LDDJR\|UxRTFyIH7N	MoDpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl6Mke4N\|EoRjF7OEK3PFMyRC:jPh?=
human T-cell	MWnGeY5kfGmxbjDhd5NigQ>?			NVTJe285UW5idnn0do8hcW6qaXLpeI9zgSCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJHQu[2WubDDwdo9lfWO2aX;uJI9nKGy7bYDoc4tqdmViSVytNkwhUUN3ME24MlEhdk1?	NUHHdVE5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxN{WzO\|M{OSd-N{WzO\|M{OTxxYU6=
human Jurkat cells	M3LUbmZ2dmO2aX;uJIF{e2G7		MoDQNUBp	NYiwZXdPSW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCqdX3hckBLfXKtYYSgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCjboTpMWNFOy:FREK4JIFvfGmkb3T5MYlv\HWlZXSgTWwuOiCycn;keYN1cW:wIITy[YF1\WRiZn;yJFEhcHJiYnXmc5JmKGGwdHmtR2Q{N0OGMkigZY51cWKxZImgZ4hidGynbnflJI1m[XO3cnXkJIFnfGW{IE[gbJJ{KGK7IHntcZVvd3O3cIDy[ZN{cW:wIHHzd4F6NCCHQ{WwQVUhdk1?	NGHySGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUmzN\|c6PSd-MUm5N\|M4QTV:L3G+
human PBMC	MlXtSpVv[3Srb36gZZN{[Xl?		NX[5b483OSCq	MUPBcpRqcW6obHHtcYF1d3K7IHHjeIl3cXS7IHnuJIh2dWGwIGDCUWMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBidnSrLVPEN{9ETDJ6IHHueIljd2S7LXnu[JVk\WRiSVytNkBxem:mdXP0bY9vKHS{ZXH0[YQh\m:{IEGgbJIh[mWob4LlJIFvfGlvQ1SzM2NFOjhiYX70bYJw\HliY3jhcIxmdmenIH3lZZN2emWmIHHmeIVzKDZiaILzJIJ6KGmvbYXuc5N2eHC{ZYPzbY9vKGG\|c3H5MEBGSzVyPUOuNUBvVQ>?	NVT4WoFxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5N\|M4QTVpPkG5PVM{Pzl3PD;hQi=>
Jurkat cells	M1zIT2Z2dmO2aX;uJIF{e2G7			MUDJcY12dm:\|dYDwdoV{e2m4ZTDhZ5Rqfmm2eTD3ZZMhdWWjc4Xy[YQh[nliaX7obYJqfGmxbjDv[kB1cGViSVytNkBxem:mdXP0bY9vKGmwIFr1dotifCClZXzsd{whUUN3ME2yJI5O	NV\CbVByRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUS2OFM{OzdpPkG0OlQ{OzN5PD;hQi=>
HepG2 cells	NWLGOZZKTnWwY4Tpc44h[XO\|YYm=			MX3Jcohq[mm2aX;uJI9nKGyrdnXyJJN1[WenIGDsZZNud2SrdX2gZoVz\2inaTDpcoZm[3Srb36gbY4hUGWyR{KgZ4VtdHNuIFnDOVA:OS54NTDuUS=>	Mm\qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3OE[xNlQoRjJ{NUi2NVI1RC:jPh?=
Jurkat	MlvLSpVv[3Srb36gZZN{[Xl?			NXXOZY5iXGinIHPvcZBwfW6mIIfhd{B1\XO2ZXSgbY4hfmm2cn:g[o9zKGmwaHnibZRqd25ib3[gTWwuOiC{ZXzlZZNmKHO2aX31cIF1\WRid3n0bEBRVUFxaX;uc416[2mwIHL5JGp2emujdDDj[Yxtey5uIFnDOVAhRSByLkCxNkDPxE1w	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek84PDd\|NUSzK\|44PDd\|NUSzQE9iRg>?
mouse spleen cells	MVHGeY5kfGmxbjDhd5NigQ>?			NF7zeXZVcGViY3;tdI92dmRid3HzJJRme3SnZDDpckB3cXS{bzDmc5IhcW6qaXLpeIlwdiCxZjDwdo9tcW[ncnH0bY9vKGmwIFLESlEhdW:3c3Wgd5Bt\WWwIHPlcIx{KHO2aX31cIF1\WRid3n0bEBkd26lYX7heoFtcW5iQTCoR49vSSlwLDDJR\|UxKD1iMD6wOEDPxE1w	MoLZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwPzR5M{W0N{c,PzR5M{W0N\|ww[T5?
Sf9	NWr4PXFXTnWwY4Tpc44h[XO\|YYm=			M2juXolvcGmkaYTpc44hd2ZiVnXyZZBidWmuIIP0bY12dGG2ZXSgRXRRKGi7ZILvcJl{cXNiaX6gcYVu[nKjbnXzJIZzd21iTVTSNU1mgHC{ZYPzbY5oKFOoOTDj[YxteyxiS3mgQUAxNjB{IN88UU4>	M{nGVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493Nzd3MUSyOlMoRjd3MUSyOlM9N2F-
LLC-PK1	MonESpVv[3Srb36gZZN{[Xl?			MYT0doFve2WyaYTo[Yxq[WxidILhcpNxd3K2IDjiZZNidCC2bzDhdIlk[WxrIHnuJG1FWjFvZYjwdoV{e2mwZzDMUGMuWEtzIHPlcIx{NCCNbTC9JFgvPCEQvF2u	M4rxcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493Nzd4OEGwOVkoRjd4OEGwOVk9N2F-
HeLa	NIjHWpNHfW6ldHnvckBie3OjeR?=			NF3PW3FqdmirYnn0bY9vKG:oIFzUR\|QhfXC2YXvlJIlvKG2nbXLyZY5mKH[nc3njcIUh\nKxbTDNVnAyNWW6cILld5NqdmdiSHXMZUBk\WyuczygT4khRSB3IN88UU4>	MlSzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwPzl4MUewOkc,Pzl4MUewOlww[T5?
Caco-2	MU\GeY5kfGmxbjDhd5NigQ>?			MWr0doFve2WyaYTo[Yxq[WxidILhcpNxd3K2IDjiZZNidCC2bzDhdIlk[WxrIHnuJGNi[29vMjDj[YxteyxiS32gQUA{NjhizszNMi=>	NW\VNZQ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxOEi0NlQ2Oid-OEi0NlQ2OjxxYU6=
spleen	M1\Qb2Z2dmO2aX;uJIF{e2G7			MlHXSYZn\WO2IH;mJINwdXCxdX7kJI9vKEmOLUKgdJJw\HWldHnvckBnem:vIHHscI9idnSrZ3XuMZN1cW23bHH0[YQhdW:3c3Wgd5Bt\WWwIHPlcIx{NCCLQ{WwJF0hOC5yMTFOwG0v	NIPXe5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi96OEmzPFM6Lz56OEmzPFM6RC:jPh?=
COS	NI\0bY1HfW6ldHnvckBie3OjeR?=			NE\5bIhqdmirYnn0bY9vKG:oIGTheZJw[2ixbHH0[UB2eHSja3WgbY4hSVOEVD3lfJBz\XO\|aX7nJGNQWyClZXzsd{whU2liPTCyOEDPxE1w	NX:2TpR2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxOUS1PFc5PSd-OUS1PFc5PTxxYU6=
LLC-PK1	MnzjSpVv[3Srb36gZZN{[Xl?			M{HTW4lvcGmkaYTpc44hd2ZiRH;4c5J2[mmlaX6geJJidnOncHn0bIVtcWGuIITyZY5{eG:{dDCoZoF{[WxidH:gZZBq[2GuKTCoSIlod3irbkqgNE45KHWPKTDpckBOTFJzLXX4dJJme3OrbnegUGxENVCNMTDj[YxteyxiSVO1NEA:KDNwNk[g{txONg>?	NVraUZg{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxOUmxOFc6Oid-OUmxOFc6OjxxYU6=
CEM/VLB100	MX3GeY5kfGmxbjDhd5NigQ>?			MX7pcohq[mm2aX;uJI9nKEOjbHPlbY4uSU1iZX\mcJV5KGmwIFPFUU9XVEJzMECgZ4VtdHNuIFvpJF0hOS56IN88UU4>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODF7OEKyO{c,OTBzOUiyNlc9N2F-
HEK	M3rGNmZ2dmO2aX;uJIF{e2G7			NUD2W\|VscW6qaXLpeIlwdiCxZjDCUWchfXC2YXvlJIlvKG2nbXLyZY5mKH[nc3njcIV{KG[{b32gUZJxOi2neIDy[ZN{cW6pIFjFT{Bk\WyuczygT4khRSBzMDFOwG0v	MnrsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB2MkG2OVgoRjFyNEKxOlU5RC:jPh?=
HEK	MmHzSpVv[3Srb36gZZN{[Xl?			NVHsdJVDcW6qaXLpeIlwdiCxZjDCUWchfXC2YXvlJIlvKG2nbXLyZY5mKH[nc3njcIV{KG[{b32gUXJROi2neIDy[ZN{cW6pIFjFT{Bk\WyuczygT4khRSB{MTFOwG0v	NHPX[Jg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMESyNVY2QCd-MUC0NlE3PTh:L3G+
HeLa	MVHGeY5kfGmxbjDhd5NigQ>?			NGjrXG1qdmirYnn0bY9vKG:oIGTheZJw[2ixbHH0[UB2eHSja3WgbY4hVlSFUD3lfJBz\XO\|aX7nJGhmVGFiY3XscJMtKEmFNUCgQUAyKM7:TT6=	NEnEUHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMEW2OVg1Oyd-MUC1OlU5PDN:L3G+
LLC-PK1	M{\qbGZ2dmO2aX;uJIF{e2G7			M4Lt[YlvcGmkaYTpc44hd2ZiTGTDOEB2eHSja3WgbY4hdWWvYoLhcoUhfmW\|aXPs[ZMh\nKxbTDNVnAzNWW6cILld5NqdmdiTFzDJHBMOSClZXzsd{whU2liPTC0Mlch\|ryPLh?=	M1PlWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyNUewNFQ6Lz5zMEW3NFA1QTxxYU6=
Sf9	NWDhVnpMTnWwY4Tpc44h[XO\|YYm=			NXjBNJlKcW6qaXLpeIlwdiCxZjDUZZVzd2Oqb3zheIUhfXC2YXvlJIlvKG2nbXLyZY5mKH[nc3njcIV{KG[{b32gRpNmeC2neIDy[ZN{cW6pIGPmPUBk\WyuczygT4khRSByLkOg{txONg>?	NX\4cIRxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUC2OFg1PzBpPkGwOlQ5PDdyPD;hQi=>
Caco-2	NUHnOGNMTnWwY4Tpc44h[XO\|YYm=			NHzPVoNqdmirYnn0bY9vKG:oIFTp[495cW5idILhcpNmeGm2aHXsbYFtKHS{YX7zdI9zfCBqYnHzZYwhfG9iYYDpZ4FtMSBqRHnnc5hqdjpiNTD1UUkhcW5iQ3Hjc{0zKGOnbHzzMEBKSzVyIE2gNU4{KM7:TT6=	Mni4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB6MkCxN\|coRjFyOEKwNVM4RC:jPh?=
CEM/VLB100	MYrGeY5kfGmxbjDhd5NigQ>?			Mn;WbY5pcWKrdHnvckBw\iCFYXzj[YlvNUGPIHXm[ox2gCBqQ3HsZ4Vqdi2DTUqgNE4zPSC3TTmgbY4hS0WPL2\MRlExOCClZXzsd{whUUN3MDC9JFMvPDFizszNMi=>	NYjvc5lKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUC4PVEyOTRpPkGwPFkyOTF2PD;hQi=>
Sf9	MmL3SpVv[3Srb36gZZN{[Xl?			NIna[mxqdmirYnn0bY9vKG:oIFHUVIF{\SCrbjDt[Y1jemGwZTD2[ZNq[2ynIH\yc40hSkOUUD3lfJBz\XO\|aX7nJHNnQSClZXzsd{whU2liPTCwMlUh\|ryPLh?=	NHfLb\|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUSzO\|M5OCd-MUG0N\|c{QDB:L3G+
NIH-3T3-G185	M2XWRmZ2dmO2aX;uJIF{e2G7			NEXHb5RqdmirYnn0bY9vKG:oIFTheY5wenWkaXPpckBm\m[udYigbY4hVkmKLUPUN{1IOTh3IHPlcIx{NCCLQ{WwJF0hOS52IN88UU4>	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTdzNkWxOEc,OTF5MU[1NVQ9N2F-
NIH-3T3-G185	MYXGeY5kfGmxbjDhd5NigQ>?			NWnieZZrcW6qaXLpeIlwdiCxZjDDZYxk\WmwLVHNJIVn\my3eDDpckBPUUhvM2SzMWcyQDViY3XscJMtKEmFNUCgQUAyNjdizszNMi=>	NWLvO2hXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUG3NVY2OTRpPkGxO\|E3PTF2PD;hQi=>
NIH-3T3-G185	MYLGeY5kfGmxbjDhd5NigQ>?			M{i3cYlvcGmkaYTpc44hd2ZiUnjv[IFucW6nIEGyN{Bm\m[udYigbY4hVkmKLUPUN{1IOTh3IHPlcIx{NCCLQ{WwJF0hOS55IN88UU4>	M{Hnc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzN{G2OVE1Lz5zMUexOlUyPDxxYU6=
NIH-3T3-G185	NXHmN4x2TnWwY4Tpc44h[XO\|YYm=			NU\M[JNIcW6qaXLpeIlwdiCxZjDMSHMuPzVzIHXm[ox2gCCrbjDOTWguO1R\|LVexPFUh[2WubIOsJGlEPTBiPTCxMlgh\|ryPLh?=	NVLK[4ZjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUG3NVY2OTRpPkGxO\|E3PTF2PD;hQi=>
NIH-3T3-G185	NHnrZpRHfW6ldHnvckBie3OjeR?=			NFn3XVRqdmirYnn0bY9vKG:oIGTleJJidWW2aInsdo9{[W2rbnWg[YZndHW6IHnuJG5KUC1\|VEOtS\|E5PSClZXzsd{whUUN3MDC9JFIvOSEQvF2u	M3vDelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzN{G2OVE1Lz5zMUexOlUyPDxxYU6=
NIH-3T3-G185	M4DUemZ2dmO2aX;uJIF{e2G7			NVjx[G1RcW6qaXLpeIlwdiCxZjDGcJVwNTNvQV2g[YZndHW6IHnuJG5KUC1\|VEOtS\|E5PSClZXzsd{whUUN3MDC9JFIvPCEQvF2u	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTdzNkWxOEc,OTF5MU[1NVQ9N2F-
NIH-3T3-G185	MUPGeY5kfGmxbjDhd5NigQ>?			MojNbY5pcWKrdHnvckBw\iCMQz2xJIVn\my3eDDpckBPUUhvM2SzMWcyQDViY3XscJMtKEmFNUCgQUA1NjNizszNMi=>	MknvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF5MU[1NVQoRjFzN{G2OVE1RC:jPh?=
HCT15	NWHoNHNJTnWwY4Tpc44h[XO\|YYm=	MW[wMlQhfG9iNj6zJJVoN22O		MVPNc4R2dGG2aX;uJI9nKFBvZ4CgbY4hcHWvYX6gTGNVOTViY3XscJMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gSGlPUUJvaX7keYNm\CCleYTveI95cWOrdImgZZQhOC52IITvJFYvOyC3Zz;tUE4>	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTd3NE[wNkc,OTF5NUS2NFI9N2F-
UO31	MU\GeY5kfGmxbjDhd5NigQ>?	NFy1WIUxNjRidH:gOk4{KHWpL33M		MV\Nc4R2dGG2aX;uJI9nKFBvZ4CgbY4hcHWvYX6gWW8{OSClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDETW5KSi2rbnT1Z4VlKGO7dH;0c5hq[2m2eTDheEAxNjRidH:gOk4{KHWpL33MMi=>	NY\xN\|VDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUG3OVQ3ODJpPkGxO\|U1PjB{PD;hQi=>
CAKI1	Mkn6SpVv[3Srb36gZZN{[Xl?	M3XKNVAvPCC2bzC2MlMhfWdxbVy=		NGfvelNOd2S3bHH0bY9vKG:oIGCt[5AhcW5iaIXtZY4hS0GNSUGgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hTEmQSVKtbY5lfWOnZDDjfZRwfG:6aXPpeJkh[XRiMD60JJRwKDZwMzD1[{9uVC5?	NVzDfZFNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUG3OVQ3ODJpPkGxO\|U1PjB{PD;hQi=>
MDA-435/LCC6 and MDA-435/LCC6-MDRI	M13hZ2Z2dmO2aX;uJIF{e2G7			M1;oZmNwdmOnboTyZZRqd25idHjheEBz\WS3Y3XzJJRp\SCmaX\m[ZJmdmOnIHnuJJJmfmW{c3HsJI9nKESRWDDhZ4N2dXWuYYTpc44h[mW2d3XlckBOTEFvNEO1M2xESzZiYX7kJG1FSS12M{WvUGNEPi2PRGLJJINmdGy\|IHL5JFUxLS5uIFXDOVAhRSByLkWg{txONg>?	NH7WbIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUe4OFE1Oyd-MUG3PFQyPDN:L3G+
MDA-435/LCC6	MkjRSpVv[3Srb36gZZN{[Xl?			MoWySYZn\WO2IH;uJJJmfmW{c3HsJI9nKFt\|SG2tJHZDVCCjY3P1cZVt[XSrb36gbY4hVUSDLUSzOU9NS0N4IDjQ[5AudmWpYYTpeoUqKGOnbHzzMkwhTUN3MDC9JFAvPiEQvF2u	NWT5TIR1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUG3PFQyPDNpPkGxO\|g1OTR\|PD;hQi=>
MDA-435/LCC6 and MDA-435/LCC6-MDRI	MX\GeY5kfGmxbjDhd5NigQ>?			MoXKR49v[2WwdILheIlwdiC2aHH0JJJm\HWlZYOg[Iln\mW{ZX7j[UBqdiC{ZY\ldpNidCCxZjDbN2heXkKOIHHjZ5VufWyjdHnvckBj\XS5ZXXuJG1FSS12M{WvUGNEPiCjbnSgUWRCNTR\|NT;MR2M3NU2GUlmgZ4VtdHNiYomgOVAmNCCHQ{WwJF0hOC54IN88UU4>	MmHaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF5OESxOFMoRjFzN{i0NVQ{RC:jPh?=
MDA435/LCC6 MDR1	M{fxW2Z2dmO2aX;uJIF{e2G7			Mn\KdoV3\XK\|YXygc4YhXmmwYnzhd5RqdmViYXPjeY12dGG2aX;uJEhXcW6kbHHzeIlv\TpiMD6wNFUhfU1rIHnuJG1FSTR\|NT;MR2M3KE2GUkGgZ4VtdHNuIFXDOVAhRSByLk[g{txONg>?	MkX2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF5OESxOFMoRjFzN{i0NVQ{RC:jPh?=
MDA-435/LCC6 (Pgp-negative)	MX;GeY5kfGmxbjDhd5NigQ>?			MnzmSYZn\WO2IH;uJJJmfmW{c3HsJI9nKESRWDDhZ4N2dXWuYYTpc44hcW5iTVTBMVQ{PS:OQ1O2JEhR\3BvbnXnZZRqfmVrIHPlcIx{NixiRVO1NEA:KDBwNzFOwG0v	NYrNRW13RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUG3PFQyPDNpPkGxO\|g1OTR\|PD;hQi=>
MDA-435/LCC6	Ml7QS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?			MX\Hdo94fGhiaX7obYJqfG:{eTDhZ5Rqfmm2eTDvckBOTEFvNEO1M2xESzZiKGDndE1xd3OrdHn2[UkhcHWvYX6gZpJm[XO2IHPhcoNmeiClZXzsd{4tKEmFNUCgQUAyKM7:TT6=	MlvuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF5OESxOFMoRjFzN{i0NVQ{RC:jPh?=
MDA-435/LCC6-MDRI	NHLvPGdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=			NXfLW5B4T3Kxd4ToJIlvcGmkaYTvdpkh[WO2aY\peJkhd25iTVTBMVQ{PS:OQ1O2MW1FWkliKGDndE1v\WejdHn2[UkhcHWvYX6gZpJm[XO2IHPhcoNmeiClZXzsd{4tKEmFNUCgQUAyNjFizszNMi=>	M1;6SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzN{i0NVQ{Lz5zMUe4OFE1OzxxYU6=
BTI-TN5B1-4	NWSyOJI{TnWwY4Tpc44h[XO\|YYm=			NEXnRnpCXFBiaInkdo9tgXOrczDpckBu\W2kcnHu[UBnemGldHnvckBnem:vIFjp[4ghTmm4ZTCoRnRKNVSQNVKxMVQqKGOnbHzzMEBMdSB;IECuNVch\|ryPLh?=	NGjaNXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUe4OVY5PCd-MUG3PFU3QDR:L3G+
Jurkat	NIKzbY1HfW6ldHnvckBie3OjeR?=			NF;RNoNKdmirYnn0bY9vKG:oIIDyc4R2[3Srb36gc4YhUUxvMjDz[YNz\XSrb36gbY4hUnW{a3H0JINmdGy\|LDDJR\|UxKD1iMD6wNFch\|ryPLh?=	NYrMUnhDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUG4PFE6QDRpPkGxPFgyQTh2PD;hQi=>
Jurkat	MV7GeY5kfGmxbjDhd5NigQ>?			MlXLTY5pcWKrdHnvckBw\iCycn;keYN1cW:wIH;mJIJmfGFvZ3HsZYN1d3OrZHHz[UBKVC1{IGLHRUBqdiCMdYLrZZQh[2WubIOsJGlEPTBiPTCwMlAxQCEQvF2u	Mm\sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF6OEG5PFQoRjFzOEixPVg1RC:jPh?=
LLC-PK1	MWjGeY5kfGmxbjDhd5NigQ>?			NGDidWhqdmO{ZXHz[UBqdiCYaX7icIF{fGmwZTDpcpRz[WOnbHz1cIFzKGGlY4XteYxifGmxbjDpckBOTFJzLXX4dJJme3OrbnegUGxENVCNMTDj[YxteyxiS3mgQUAyNjNizszNMi=>	Ml\zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF7NkGxNVMoRjFzOU[xNVE{RC:jPh?=
LLC-PK1	M4T0OmZ2dmO2aX;uJIF{e2G7			NHTIW4tqdmO{ZXHz[UBqdiCFYXzj[YlvNUGPIHnueJJi[2WubIXsZZIh[WOldX31cIF1cW:wIHnuJG1FWjFvZYjwdoV{e2mwZzDMUGMuWEtzIHPlcIx{NCCNaTC9JFQvPjZizszNMi=>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTl4MUGxN{c,OTF7NkGxNVM9N2F-
MDCK	MkfESpVv[3Srb36gZZN{[Xl?			M3nITYlvcGmkaYTpc44hd2ZiRHnnc5hqdiC2cnHud4VxcXSqZXzpZYwhfHKjboPwc5J1KCikYYPhcEB1dyCjcHnjZYwqKGmwIF3EVlEu\XiycnXzd4lv\yCPRFPLJINmdGy\|LDDLbUA:KDJwMUig{txONg>?	MmG3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzM{S5OFUoRjF{MUO0PVQ2RC:jPh?=
MDCK	M1r1PGZ2dmO2aX;uJIF{e2G7			MWDpcohq[mm2aX;uJI9nKF[rbnLsZZN1cW6nIITyZY5{\XCrdHjlcIlidCC2cnHud5BwenRiKHLhd4FtKHSxIHHwbYNidCliaX6gUXJROi2neIDy[ZN{cW6pIF3ER2sh[2WubIOsJGtqKD1iOD6xNUDPxE1w	MlSyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzM{S5OFYoRjF{MUO0PVQ3RC:jPh?=
LLC-PK1	MnPJSpVv[3Srb36gZZN{[Xl?			NXfRXIc6cW6lcnXhd4UhcW5iQ3HsZ4Vqdi2DTTDpcpRz[WOnbHz1cIFzKGGlY4XteYxifGmxbjDpckBu\HJzYj3lfJBz\XO\|aX7nJGxNSy2SS{GgZ4VtdHNuIFvpJF0hOy53IN88UU4>	NXrUbXFVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUKyN\|UzPjdpPkGyNlM2OjZ5PD;hQi=>
LLC-PK1	M{\SWGZ2dmO2aX;uJIF{e2G7			M2\idIlv[3KnYYPlJIlvKEOjbHPlbY4uSU1iaX70doFk\WyudXzhdkBi[2O3bYXsZZRqd25iaX6gcYRzOWFvZYjwdoV{e2mwZzDMUGMuWEtzIHPlcIx{NCCNaTC9JFMvPjVizszNMi=>	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjJ\|NUK2O{c,OTJ{M{WyOlc9N2F-
HL-60	MmHmSpVv[3Srb36gZZN{[Xl?			NFLBdndKdmirYnn0c5J6KGGldHn2bZR6KGGpYXnud5QhUHWvYX6g[o9zdXmucHXweIll\SC{ZXPldJRweiBqRmDSLUBw\iCqdX3hckBt\XWtZX3pZUBJVC14MDDj[YxteyxiSVOyNEA:KDNwNjFOwG0v	Mn:2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJ\|NkGzPFgoRjF{M{[xN\|g5RC:jPh?=
High Five cells	NXfCbJJRTnWwY4Tpc44h[XO\|YYm=			MUfpcohq[mm2aX;uJI9nKFSjdYLvZ4hmdm:mZX;4fYNpd2yjdHWgeZB1[WunKFPzRUA{OHWPLDCzNEAmKG:oIHPvcpRzd2xrIHnuJI1mdWK{YX7lJJZme2mlbHXzJJBz\XCjcnXkJIZzd21iSHnnbEBHcX[nIHPlcIx{KGmwZnXjeIVlKHerdHigeIhmKEGEQ1KxNUBj[WO3bH;2bZJ2eyxiS3mgQUA6NjVizszNMi=>	NXHZU\|BURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUK0NFQzOzlpPkGyOFA1OjN7PD;hQi=>
MDCKII	M3XleWZ2dmO2aX;uJIF{e2G7			NEPncIpqdmirYnn0bY9vKG:oIFPldol3[XO2YYTpckB2eHSja3WgbY4hV0GWUEKt[ZhxemW\|c3nu[{BOTEONSVmgZ4VtdHNuIFvpJF0hOC5{M{ig{txONg>?	NIHHPVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkWzPFgyOyd-MUK1N\|g5OTN:L3G+
Caco-2	MWPGeY5kfGmxbjDhd5NigQ>?			MYT0doFve2WyaYTo[Yxq[WxidILhcpNxd3K2IH;mJIRq\2:6aX6gLIJie2GuIITvJIFxcWOjbDmgbY4hS2Glbz2yJINmdGy\|LDDLbUA:KDBwM{Wg{txONg>?	MlzlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJ4M{[xOVMoRjF{NkO2NVU{RC:jPh?=
SK-E2	NF3u[5RHfW6ldHnvckBie3OjeR?=			NVWzZ3o{cW6lcnXhd4UhcW5iYn;kbZB6KGmwdILhZ4VtdHWuYYKgZYNkfW23bHH0bY9vKCiEb3TpdJk7KDBwMjD1UUkhcW5iU1utSVIh[2WubIOgLIV5eHKnc4PpcochSlOHUDmsJGlEPTBiPTC3MlUh\|ryPLh?=	NHHveHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkezPVc2QSd-MUK3N\|k4PTl:L3G+
SK-E2	NEHPRmlHfW6ldHnvckBie3OjeR?=			MnzhbY5kemWjc3WgbY4h\GmqeXTyc4ZtfW:{ZYPj[YlvKGmwdILhZ4VtdHWuYYKgZYNkfW23bHH0bY9vKCimaXj5[JJw\my3b4Lld4NmcW58IEGgeW0qKGmwIGPLMWUzKGOnbHzzJEhmgHC{ZYPzbY5oKEKVRWCpMEBKSzVyIE2gO{45KM7:TT6=	MoDyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJ5M{m3OVkoRjF{N{O5O\|U6RC:jPh?=
HEK293	MkS5SpVv[3Srb36gZZN{[Xl?			MorWbY5pcWKrdHnvckBw\iCSaHHscI9q\GmwIIXweIFs\SBqUHjhcIxwcWSrbkqgNUB2VSliaX6gU2FVWC2FLXX4dJJme3OrbnegTGVMOjl\|IHPlcIx{NCCNaTC9JFAvOiEQvF2u	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPDV\|MEmwO{c,OTR3M{C5NFc9N2F-
T-cells	M2C1dGZ2dmO2aX;uJIF{e2G7			NEfjd2xKdmirYnn0bY9vKG:oIHHscI9o\W6rYzDj[Yxtey2\|dHnteYxifGWmIIDyc4xq\mW{YYTpc44hcW5ibX;1d4UhXCClZXzsd{BjgSCvaYjl[EBtgW2yaH;jfZRmKHKnYXP0bY9vKG2ndHjv[EwhUUN3MDC9JFAvODN{IN88UU4>	M3:x[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF2NUmzNVgzLz5zNEW5N\|E5OjxxYU6=
T-cells	MX\GeY5kfGmxbjDhd5NigQ>?			MknpTY5pcWKrdHnvckBw\iCjbHzv[4VvcWNiY3XscJMue3SrbYXsZZRm\CCycn;sbYZmemG2aX;uJIlvKGi3bXHuJHQh[2WubIOgZpkhdWm6ZXSgcJlueGixY4n0[UBz\WGldHnvckBu\XSqb3SsJGlEPTBiPTCwMlA4PCEQvF2u	M4XKXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF2NUmzNVgzLz5zNEW5N\|E5OjxxYU6=
PMBC	NFrRO2RHfW6ldHnvckBie3OjeR?=		MW[3NkBpenN?	M4XhfmVn\mWldDDvckBxem:uaX\ldoF1cW:wIH;mJIh2dWGwIIDldolxcGW{YXygZoxwd2RibX;uc452[2ynYYKgZ4VtdHNiKGDNRmMqKGG2IEeyJIhzKHW\|aX7nJG1VXCCjc4PhfUwhUUN3MDC9JFgvQTdizszNMi=>	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTJyM{G2N{c,OTV{MEOxOlM9N2F-
mouse spleen cells	NE[4ZmNEgXSxdH;4bYNqfHliYYPzZZk>			Mn7OR5l1d3SxeHnjbZR6KGGpYXnud5QhSkGOQj;jJI1wfXOnIIPwcIVmdiClZXzsd{whS0N3MDC9JFEvOzVizszNMi=>	MmC3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdyOEG3OlEoRjF5MEixO\|YyRC:jPh?=
MDCK2	M{LVOmZ2dmO2aX;uJIF{e2G7			MlXSTY5pcWKrdHnvckBw\iCqdX3hckBOTFJzLXTldIVv\GWwdDDhZ4N2dXWuYYTpc44hd2ZiY3HsZ4Vqdi2DTTDlfJBz\XO\|ZXSgbY4hVUSFS{KgZ4VtdHNuIFnDOVAhRSB7LkO0JO69VS5?	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ4NEOyO{c,OTd4NkSzNlc9N2F-
HEK293	NX3xflQ4TnWwY4Tpc44h[XO\|YYm=			MmTiTY5pcWKrdHnvckBw\iClcn;zd{1tcW6taX7nJI9nKGi3bXHuJHBoeCCWTUGgUFY2Wi:WTU[gUFM{QUNxVF23JGY4OjhibYX0ZY51KGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[XO\|ZYPz[YQh[XNiZIL1[{Bt\X[nbDDjZZV{cW6pIEWwKUBqdmirYnn0bY9vKG:oIHPyc5N{KGyrbnvpcoch[nliaX3teY5w[myxdDygRYN1cX[rdImgQUAxNjVizszNMi=>	M2XVbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5OES4OVY{Lz5zN{i0PFU3OzxxYU6=
HEK293	NF7ySHBHfW6ldHnvckBie3OjeR?=			M1nZOmlvcGmkaYTpc44hd2ZiY4Lvd5MudGmwa3nu[{Bw\iCqdX3hckBR\3BiVF22JGw{OzmFL2TNO{BHPzJ6QzDteZRidnRiZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCjc4Pld5Nm\CCjczDkdpVoKGyndnXsJINifXOrbnegOVAmKGmwaHnibZRqd25ib3[gZ5Jwe3NibHnub4lv\yCkeTDpcY12dm:kbH;0MEBC[3Srdnn0fUA:KDBwNjFOwG0v	NYj5VnRSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe4OFg2PjNpPkG3PFQ5PTZ\|PD;hQi=>
HEK293	NGPBVW5HfW6ldHnvckBie3OjeR?=			NHewWlVKdmirYnn0bY9vKG:oIHPyc5N{NWyrbnvpcochd2ZiaIXtZY4hWGeyIGTNN3QyQTmUL2TNOkBNOzN7Qz;UUVchTjd{OFOgcZV1[W62IHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNiYYPz[ZN{\WRiYYOg[JJ2\yCuZY\lcEBk[XW\|aX7nJFUxLSCrbnjpZol1cW:wIH;mJINzd3O\|IHzpcotqdmdiYomgbY1ufW6xYnzveEwhSWO2aY\peJkhRSBzLkGg{txONg>?	NYH0RVBZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe4OFg2PjNpPkG3PFQ5PTZ\|PD;hQi=>
HEK293	NXHVcWhqTnWwY4Tpc44h[XO\|YYm=			NWnnW4M1UW6qaXLpeIlwdiCxZjDjdo9{ey2uaX7rbY5oKG:oIHj1cYFvKFCpcDDUUVYhTjN2M2KvWG03KEx\|M{nDM3ROPyCIN{K4R{BufXSjboSg[ZhxemW\|c3XkJIlvKEiHS{K5N{Bk\WyuczDhd5Nme3OnZDDhd{BlenWpIHzleoVtKGOjdYPpcochPTBnIHnubIljcXSrb36gc4Yh[3Kxc4OgcIlvc2mwZzDifUBqdW23bn;icI91NCCDY4Tpeol1gSB;IEGxJO69VS5?	MlTrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd6NEi1OlMoRjF5OES4OVY{RC:jPh?=
HEK293	NWXPO\|ExTnWwY4Tpc44h[XO\|YYm=			M{PPbmlvcGmkaYTpc44hd2ZiY4Lvd5MudGmwa3nu[{Bw\iCqdX3hckBR\3BiVF21JGk{OD[UL2TNOkBNOzN7Qz;UUVchTjd{OFOgcZV1[W62IHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNiYYPz[ZN{\WRiYYOg[JJ2\yCuZY\lcEBk[XW\|aX7nJFUxLSCrbnjpZol1cW:wIH;mJINzd3O\|IHzpcotqdmdiYomgbY1ufW6xYnzveEwhSWO2aY\peJkhRSBzNTFOwG0v	M1myfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5OES4OVY{Lz5zN{i0PFU3OzxxYU6=
MDCK2	NXi2NGRjTnWwY4Tpc44h[XO\|YYm=	M3Szc\|ExKHWP	NHjtSmU1OCCvaX7z	NV32T2xsUW6qaXLpeIlwdiCxZjDoeY1idiC5aXzkJJR6eGViUHfwJIV5eHKnc4Pl[EBqdiCPRFPLNkBk\WyuczDhd5Nme3OnZDDhd{Bk[WylZXnuMWFOKGGlY4XteYxifGmxbjDheEAyOCC3TTDh[pRmeiB2MDDtbY5{Ng>?	M2nSUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5OU[0NVcxLz5zN{m2OFE4ODxxYU6=
A2780	NV;jPI9lTnWwY4Tpc44h[XO\|YYm=		MlGzN\|AhdWmwcx?=	M1naOmlvcGmkaYTpc44hd2ZiaIXtZY4hWGeyIHnuJGEzPzhyIHPlcIx{KGGodHXyJFMxKG2rboOgZpkhUG:nY3jzeEA{OzN2MjDhd5NigSxiSVO1NEA:KDFwNEGyOVQh\|ryPLh?=	NHnSXWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEC4N\|A{PCd-MUiwPFMxOzR:L3G+
A2780	NWHxWZo{TnWwY4Tpc44h[XO\|YYm=		NHLIcnY{OCCvaX7z	MX\Jcohq[mm2aX;uJI9nKGi3bXHuJHBoeCCrbjDBNlc5OCClZXzsd{Bi\nSncjCzNEBucW6\|IHL5JINidGOnaX6gRW0h[XO\|YYmsJGlEPTBiPTCxMlQyOjV2IN88UU4>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDB6M{CzOEc,OThyOEOwN\|Q9N2F-
Caco-2	NFXMToRHfW6ldHnvckBie3OjeR?=			NGKy[XNKdmirYnn0bY9vKG:oIGCt[4x6[2:ycn;0[YlvNW2nZHnheIVlKFt\|SG32bY5jdGG\|dHnu[UB1emGwc4DvdpQhcW5iaIXtZY4hS2Glbz2yJINmdGy\|LDDFR\|UxKD1iNEWuOUDPxE1w	M4HVb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUK0OVkzLz5zOEWyOFU6OjxxYU6=
A2780	M4DIcmZ2dmO2aX;uJIF{e2G7			NGjDZ4RKdmirYnn0bY9vKG:oIGCt[5AhcW5iaIXtZY4h[WS{aXHtfYNqdi2{ZYPpd5RidnRiQUK3PFAh[2WubIOgZpkhUG:nY3jzeEA{OzN2MjDhd5NigSxiSVO1NEA:KDFwNEGyOVQh\|ryPLh?=	NFj5W4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[3PFQ6PSd-MUi2O\|g1QTV:L3G+
Huh-9-13	M{LKZ2FvfGm4aYLhcEBie3OjeR?=		NILNNpk{KGSjeYO=	MXLBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDCTWxPKDJyNkGtdoV{cXO2YX70JGhEXiCpZX7veJlx\SBzYjDpcoZm[3SnZDDpckBpfW2jbjDIeYguQS1zMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hfmm{YXygdoVxdGmlYYTpc44h[W[2ZYKgN{Bl[Xm\|IHL5JJF2[W62aYTheIl3\SCUVD3QR3ItKEWFNUCgQUAxNjByNDFOwG0v	MlLiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzMESwNVMoRjF7MUC0NFE{RC:jPh?=
Huh-9-13	MkXlRY51cX[rcnHsJIF{e2G7		MVmzJIRigXN?	MoHpRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgZ49ueG:3bnStdoV{cXO2YX70JGhEXiCpZX7veJlx\SBzYjDpcoZm[3SnZDDpckBpfW2jbjDIeYguQS1zMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hfmm{YXygdoVxdGmlYYTpc44h[W[2ZYKgN{Bl[Xm\|IHL5JJF2[W62aYTheIl3\SCUVD3QR3ItKEWFNUCgQUAxNjN3IN88UU4>	MkPsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzMESwNVMoRjF7MUC0NFE{RC:jPh?=
Huh-9-13	MmP4RY51cX[rcnHsJIF{e2G7		MYCzJIRigXN?	M{Py[GFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JFIoNUNvbXX0bJltNTJpLX\seY9zdy2leYTp[Ilv\S2{ZYPpd5RidnRiSFPWJIdmdm:2eYDlJFFjKGmwZnXjeIVlKGmwIHj1cYFvKEi3aD25MVE{KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjD2bZJidCC{ZYDsbYNifGmxbjDh[pRmeiB\|IHThfZMh[nlicYXhcpRqfGG2aY\lJHJVNVCFUjygSWM2OCB;IECuOEDPxE1w	NI\mVJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGwOFAyOyd-MUmxNFQxOTN:L3G+
Huh-9-13	MnXWRY51cX[rcnHsJIF{e2G7		Mke1N{Bl[Xm\|	NXfkSZY1SW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhXlhiOUWwMZJme2m\|dHHueEBJS1ZiZ3Xuc5R6eGViMXKgbY5n\WO2ZXSgbY4hcHWvYX6gTJVpNTlvMUOgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKH[rcnHsJJJmeGyrY3H0bY9vKGGodHXyJFMh\GG7czDifUByfWGwdHn0ZZRqfmViUmStVGNTNCCHQ{WwJF0hOC52OTFOwG0v	M4fv[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUC0NFE{Lz5zOUGwOFAyOzxxYU6=
Huh-9-13	MVTBcpRqfmm{YXygZZN{[Xl?		M1j5WVMh\GG7cx?=	M3PT[GFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JHI1PzlvcnXzbZN1[W62IFjDWkBo\W6xdInw[UAy[iCrbn\lZ5Rm\CCrbjDoeY1idiCKdXitPU0yOyClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6geolz[WxicnXwcIlk[XSrb36gZYZ1\XJiMzDkZZl{KGK7IIH1ZY51cXSjdHn2[UBTXC2SQ2KsJGVEPTBiPTCxMlk5KM7:TT6=	M4[3eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUC0NFE{Lz5zOUGwOFAyOzxxYU6=
Huh-9-13	NHr2WGhCdnSrdnnyZYwh[XO\|YYm=		NUf1RZFuOyCmYYnz	Mo\6RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgZ5lkdG:\|cH;ybY5mNXKnc3nzeIFvfCCKQ2[g[4Vvd3S7cHWgNYIhcW6oZXP0[YQhcW5iaIXtZY4hUHWqLUmtNVMh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwII\pdoFtKHKncHzpZ4F1cW:wIHHmeIVzKDNiZHH5d{BjgSCzdXHueIl1[XSrdnWgVnQuWEOULDDFR\|UxKD1iMz64OUDPxE1w	NEjVN3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGwOFAyOyd-MUmxNFQxOTN:L3G+
A2780/ADR	NFrFRm9HfW6ldHnvckBie3OjeR?=			MUDJcohq[mm2aX;uJI9nKFBvZ3z5Z49xem:2ZXnuMY1m\GmjdHXkJI12dHSrZIL1[{Bz\XOrc4ThcoNmKGmwIHHkdolidXmlaX6tdoV{cXO2YX70JIh2dWGwIFGyO\|gxN0GGUjDj[YxteyCkeTDjZYxk\WmwIFHNJIF{e2G7LDDJR\|UxKD1iMT60JO69VS5?	NWjaZm5lRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmyOVA5OzRpPkG5NlUxQDN2PD;hQi=>
C2C12	NELVd4NHfW6ldHnvckBie3OjeR?=	M3vhZlAvOSC3Zz;tcC=>	M13tWFMh\GG7cx?=	MYTJcohq[mm2aX;uJI9nKGineH;z[U03NXCqb4PwbIF1\SCmZXj5[JJw\2WwYYPlMYlv\HWlZXSgZ4VtdCCmaX\m[ZJmdnSrYYTpc44hcW5ibX;1d4UhSzKFMUKgZ4VtdHNiYYPz[ZN{\WRiYYOgcZlwe2mwIHjlZZZ6KGOqYXnuJIZtfW:{ZYPj[Y5k\SCjdDCwMlEhfWdxbXyg[o9zKDNiZHH5d{4>	NH33eWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEC4NVg2PSd-MkCwPFE5PTV:L3G+
C2C12	M{PnfWZ2dmO2aX;uJIF{e2G7			NGHBZ2NKdmirYnn0bY9vKG:oIIPldpVuKHerdHjkdoF4[WxvaX7keYNm\CClZXzsJIRq\m[ncnXueIlifGmxbjDpckBud3W\|ZTDDNmMyOiClZXzsd{Bie3Onc4Pl[EBieyCveX;zbY4hcGWjdomgZ4hicW5iZYjwdoV{e2mxbj6=	M{DC[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMEixPFU2Lz5{MEC4NVg2PTxxYU6=
HuH7	M{\VZ2FvfGm4aYLhcEBie3OjeR?=		MnK2OFghcHK\|	MUDBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDIR3Yhe3WkdInw[UAy[iCFb36xJIlv\mWldHXkJIlvKGi3bXHuJGh2UDdiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJJZqemGuIGLORUBt\X[nbDDh[pRmeiB2ODDodpMh[nliTWTTJIF{e2G7LDDFR\|UxKD1iMD6yNUDPxE1w	M1PuV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUe2PFk1Lz5{MEG3Olg6PDxxYU6=
HuH7	NU[2To5VSW62aY\pdoFtKGG\|c3H5		NXjLXlF{PDhiaILz	MV;BcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDjfYNtd3Oyb4LpcoUhSS2{ZYPpd5RidnRiSFPWJJN2[nS7cHWgNYIhS2:wMTDpcoZm[3SnZDDpckBpfW2jbjDIeWg4KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjD2bZJidCCUTlGgcIV3\WxiYX\0[ZIhPDhiaILzJIJ6KE2WUzDhd5NigSxiRVO1NEA:KDNwM{mg{txONg>?	NHjHUY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG3Olg6PCd-MkCxO\|Y5QTR:L3G+
T-cells	NUH6b5QxUW2vdX7vd5VxeHKnc4PpeoUh[XO\|YYm=		M2LrNVczKGi{cx?=	NX30T4ltUW2vdX7vd5VxeHKnc4PpeoUh[WO2aY\peJkhcW5iQlHMRk9kKG2xdYPlJHQh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDhcpRqNUOGMz;hcpRqNUOGMkitd5RqdXWuYYTl[EBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvODZizszNMi=>	NGTlXnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUGzNVExPCd-MkGxN\|EyODR:L3G+
T-cells	MnPiR5l1d3SxeHnjbZR6KGG\|c3H5		NIfSb2M1QCCqcoO=	NXrJRWpIS3m2b4TvfIlkcXS7IHHnZYlve3RiQlHMRk9kKG2xdYPlJHQh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygR2M2OCB;IEG1MlgzKM7:TT6=	NXPwSpRIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxN\|EyODRpPkKxNVMyOTB2PD;hQi=>
HCT15	M3nFXWZ2dmO2aX;uJIF{e2G7	NWnzS2hmOTBidV2=		NHnFeXNKdmirYnn0bY9vKG:oIF3EVlEhcW5iaIXtZY4hUEOWMUWgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4Ft[2Wrbj3BUUBm\m[udYigZZQhOTBidV2gZpkh\my3b4Lld4NmdmOnIHHzd4F6Ng>?	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN2OES2NUc,OjF\|NEi0OlE9N2F-
T-cells	MmfMTY1ufW6xc4XwdJJme3OrdnWgZZN{[Xl?		MmXQPVYhcHK\|	Mo\ETY1ufW6xc4XwdJJme3OrdnWgZYN1cX[rdImgbY4hSkGOQj;jM2M2P0KOL{[gcY92e2ViVDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGGubH;hcpRq\2WwLXnu[JVk\WRiY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDl4IHjyd{BjgSCvZXHzeZJqdmdiW{PIYZRpgW2rZHnu[UB2eHSja3WgZpkhdWm6ZXSgcJlueGixY4n0[UBz\WGldHnvckBie3OjeTygTWM2OCB;IECuNFE1KM7:TT6=	NIjxcYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS1OlUzPCd-MkG0OVY2OjR:L3G+
mouse spleen cells	M4PsTGZ2dmO2aX;uJIF{e2G7			MkC4TY5pcWKrdHnvckBw\iC\|ZYLpcoUheGGubXn0c5ltfHKjboPm[ZJie2ViaX6gcY92e2Vic4Ds[YVvKGOnbHzzMi=>	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR3NkWyOEc,OjF2NU[1NlQ9N2F-
HCT116	MVzGeY5kfGmxbjDhd5NigQ>?	NEm4RZkyOCC3TR?=	NV:4XHI4OzBibXnudy=>	MYHNc4R2dGG2aX;uJI9nKEKFUmCgbY4hcHWvYX6gTGNVOTF4IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnueJJi[2WubIXsZZIh[WOldX31cIF1cW:wIH;mJI1qfG:6YX70do9v\SCjdDCxNEB2VSCjZoTldkA{OCCvaX7zJIJ6KG[ub4etZ5l1d22ndIL5Mi=>	NEHvW5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS4PFY5Pid-MkG0PFg3QDZ:L3G+
Sf21	M1u0WWZ2dmO2aX;uJIF{e2G7			NVzNcZpJUW6qaXLpeIlwdiCxZjDoeY1idiCEU1XQJIV5eHKnc4Pl[EBqdiCybHHzcYEhdWWvYoLhcoUhfmW\|aXPs[ZMhd2ZiU3[yNUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFHUVE1l\XCnbnTlcpQhYzOKXYTheZJw[2ixbHH0[UB2eHSja3WsJGlEPTBiPTCwMlUh\|ryPLh?=	NIToU5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm2OVYzOyd-MkG5OlU3OjN:L3G+
Sf21	M4f0OGZ2dmO2aX;uJIF{e2G7			MljkTY5pcWKrdHnvckBw\iCVcILh[5VmNUSjd3zlfUBz[XRiQoPldEBmgHC{ZYPz[YQhcW5icHzhd41iKG2nbXLyZY5mKH[nc3njcIV{KG:oIGPmNlEh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDBWHAu\GWyZX7k[Y51KFt\|SG30ZZVzd2Oqb3zheIUhfXC2YXvlMEBKSzVyIE2gNE43KM7:TT6=	NGO5fog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm2OVYzOyd-MkG5OlU3OjN:L3G+
T-cells	M{fYbGZ2dmO2aX;uJIF{e2G7			NU\1S\|BqUW6qaXLpeIlwdiCxZjDDSFQh\XiycnXzd4lwdiCrbjDoeY1idiCFRESrJHQh[2WubIOsJGlEPTBiPTC4Mlk4KM7:TT6=	M3\yUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUCxNVM2Lz5{MkGwNVE{PTxxYU6=
L929	NYC2[FViS3m2b4TvfIlkcXS7IHHzd4F6		NV\wOHoxPzJiaILz	MVLDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDMPVI6KGOnbHzzJIFnfGW{IEeyJIhzeyxiSVO1NEA:KDN\|Lkmg{txONg>?	NXrtS4l1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzNlA1ODJpPkKyN\|IxPDB{PD;hQi=>
CCRF-CEM/VCR1000	M1r4fmZ2dmO2aX;uJIF{e2G7		NWr1WY5GOjRyIIPlZ5M>	NGDkeHhKdmirYnn0bY9vKG:oIGCt[4x6[2:ycn;0[YlvNW2nZHnheIVlKGSjdX7vdpVjcWOrbjDl[oZtfXhiZoLvcUBpfW2jbjDDR3JHNUOHTT;WR3IyODByIHPlcIx{KGGodHXyJFI1OCC\|ZXPzJIJ6KE[DQ2Og[oxwfyCleYTvcYV1emmlIHHuZYx6e2m\|LDDJR\|UxKD1iMD6xNFI{OyEQvF2u	NWG5Zmx6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0OVI1OTJpPkKyOFUzPDF{PD;hQi=>
mouse lymph node cells	M3W1OmludXWwb4P1dJBz\XO\|aY\lJIF{e2G7		NHj1PGw4OiCqcoO=	MYLJcY12dm:\|dYDwdoV{e2m4ZTDhZ5Rqfmm2eTDpckBidnSrLVPEN{9idnSrLVPEPEBkdy2\|dHnteYxifGWmIFLhcIIw[yCvb4Xz[UBtgW2yaDDuc4RmKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCCycn;sbYZmemG2aX;uJIFnfGW{IEeyJIhzeyCkeTDFUGlUSSxiSVO1NEA:KDBwMEeg{txONg>?	NHfYXW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS5OFYyPid-MkK0PVQ3OTZ:L3G+
mouse lymph node cells	NXK5W\|NYS3m2b4TvfIlkcXS7IHHzd4F6		Mlj2OFghcHK\|	MmLXR5l1d3SxeHnjbZR6KGGpYXnud5QhSmGuYj;jJI1wfXOnIHz5cZBpKG6xZHWgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiQ1O1NEA:KDFyLkGg{txONg>?	M4fTfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEm0OlE3Lz5{MkS5OFYyPjxxYU6=
HEK293	M2O5UmZ2dmO2aX;uJIF{e2G7		NFfyPJQ2KG2rboO=	MWLJcohq[mm2aX;uJI9nKGi3bXHuJIxqfmW{IF;BWHAySjNiZYjwdoV{e2WmIHnuJGhGUzJ7MzDGcJAuUW5iY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJHs{UF2HMUetZoV1[UdidYD0ZYtmKGmwY4XiZZRm\CCob4KgOUBucW6\|IHL5JJNkcW62aXzsZZRqd25iY3;1cpRqdmduIFvpJF0hOS5{IN88UU4>	NXO1[2ZZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1OFExPjhpPkKyOVQyODZ6PD;hQi=>
HEK293	MofHSpVv[3Srb36gZZN{[Xl?			NXrnSXRlUW6qaXLpeIlwdiCxZjDoeY1idiCuaY\ldkBQSVSSMVKxJIV5eHKnc4Pl[EBqdiCKRVuyPVMhTmyyLVnuJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCHMUetZoV1[UdidYD0ZYtmKGK7IIPjbY51cWyuYYTpc44h[2:3boTpcoctKEurIE2gNU4{KM7:TT6=	MnnlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3NEGwOlgoRjJ{NUSxNFY5RC:jPh?=
HEK293	NETScnFHfW6ldHnvckBie3OjeR?=		NWnqdXpxPSCvaX7z	MlezTY5pcWKrdHnvckBw\iCqdX3hckBtcX[ncjDPRXRROUJ\|IHX4dJJme3OnZDDpckBJTUt{OUOgSoxxNUmwIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBcO0ifRUG3MYJmfGGJIIXweIFs\SCrbnP1ZoF1\WRiZn;yJFUhdWmwczDifUB{[2mwdHnscIF1cW:wIHPveY51cW6pLDDJR\|UxKD1iMT6zJO69VS5?	Ml7RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3NEGwOlgoRjJ{NUSxNFY5RC:jPh?=
HEK293	NWLHVZdYTnWwY4Tpc44h[XO\|YYm=			NIT4TmZKdmirYnn0bY9vKG:oIHj1cYFvKGyrdnXyJG9CXFBzQkGg[ZhxemW\|c3XkJIlvKEiHS{K5N{BHdHBvSX6gZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKEVzNz3i[ZRiTyC3cIThb4Uh[nlic3PpcpRqdGyjdHnvckBkd3WwdHnu[{whUUN3MDC9JFEvPCEQvF2u	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV2MUC2PEc,OjJ3NEGwOlg9N2F-
HEK293	NHLvZ\|FHfW6ldHnvckBie3OjeR?=		Mm\0OUBucW6\|	MlK3TY5pcWKrdHnvckBw\iCqdX3hckBtcX[ncjDPRXRROkJzIHX4dJJme3OnZDDpckBJTUt{OUOgSoxxNUmwIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBcO0ifRUPTJJVxfGGtZTDpcoN2[mG2ZXSg[o9zKDVibXnud{BjgSC\|Y3nueIltdGG2aX;uJINwfW62aX7nMEBMcSB;IEO2JO69VS5?	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV2MUC2PEc,OjJ3NEGwOlg9N2F-
HEK293	MVzGeY5kfGmxbjDhd5NigQ>?		MW[1JI1qdnN?	MXLJcohq[mm2aX;uJI9nKGi3bXHuJIxqfmW{IF;BWHAzSjFiZYjwdoV{e2WmIHnuJGhGUzJ7MzDGcJAuUW5iY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJHs{UF2HM2OgeZB1[WunIHnuZ5Vj[XSnZDDmc5IhPSCvaX7zJIJ6KHOlaX70bYxt[XSrb36gZ492dnSrbnesJGlEPTBiPTCzO{DPxE1w	MnzlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3NEGwOlgoRjJ{NUSxNFY5RC:jPh?=
T-cells	NUPWO5ZNUW2vdX7vd5VxeHKnc4PpeoUh[XO\|YYm=		M3XOd\|I1KGi{cx?=	MmjjTY1ufW6xc4XwdJJme3OrdnWgZYN1cX[rdImgbY4hSkGOQj;jJI1wfXOnIGSgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCFb37BMYlv\HWlZXSgWEBk\WyuIIDyc4xq\mW{YYTpc44hcW6ldXLheIVlKDJ2IHjyd{Bxd3O2IFPvcmEucW6mdXP0bY9vKG[xcjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNk4yOiEQvF2u	M2P4TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{K3N\|Y6Lz5{MkeyO\|M3QTxxYU6=
2008	Mnr6SpVv[3Srb36gZZN{[Xl?	MonvNVAhfU1?	M1nKSVMxKG2rboO=	MoCxTY5pcWKrdHnvckBw\iCqdX3hckBOWlBzIHX4dJJme3OnZDDpckAzODB6IHPlcIx{KGG2IEGwJJVOKHC{ZXnuZ5Vj[XSnZDDmc5IhOzBibXnud{BxemmxcjD0c{Bk[WylZXnuJGFOKGGmZHn0bY9vKG2nYYP1doVlKGW4ZYL5JFYxKHOnY4OgeZAhfG9iOUCgcYlveyCkeTDjZYxk\WmwIFHNJIFk[3WvdXzheIlwdiCjc4PhfU4>	M2q1U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEG3PFg5Lz5{M{CxO\|g5QDxxYU6=
A2780adr	M17Ed2Z2dmO2aX;uJIF{e2G7	NF20V48yOCC3TR?=	M4j3bFMxKG2rboO=	NFXIR41KdmirYnn0bY9vKG:oIHj1cYFvKFBvZ4Cgc5ZmemW6cILld5Nm\CCrbjDkc5hwenWkaXPpckBz\XOrc4ThcpQhSTJ5OEDh[JIh[2WubIOgZZQhOTBidV2gdJJmcW6ldXLheIVlKG[xcjCzNEBucW6\|IIDybY9zKHSxIHPhcINmcW5iQV2gZYRlcXSrb36gcYVie3W{ZXSg[ZZmenliNkCgd4VkeyC3cDD0c{A6OCCvaX7zJIJ6KGOjbHPlbY4hSU1iYXPjeY12dGG2aX;uJIF{e2G7Lh?=	M4TjXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEG3PFg5Lz5{M{CxO\|g5QDxxYU6=
HL60	M{jkbWZ2dmO2aX;uJIF{e2G7	NWDUeXdUPSC3TR?=	MWG0NEBucW6\|	NWXuNplLUW6qaXLpeIlwdiCxZjDDZVIsNWmwZIXj[YQhdWm2b3Poc45lemmjbDDw[ZJu\WGkaXzpeJkhfHKjboPpeIlwdiCrbjDoeY1idiCKTE[wJINmdGy\|IHH0JFUhfU1iYX\0[ZIhPDBibXnud{Bz\WyjdHn2[UB1dyClb370do9tNg>?	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB{NkC4N{c,OjNyMk[wPFM9N2F-
RPMI1788	M1z2XmludXWwb4P1dJBz\XO\|aY\lJIF{e2G7		MXO2JIRigXN?	MUDJcY12dm:\|dYDwdoV{e2m4ZTDhZ5Rqfmm2eTDpckBpfW2jbjDSVG1KOTd6ODDj[YxteyClb3P1cJR2emWmIIfpeIghcHWvYX6gVGJOSyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKFt\|SG30bJlucWSrbnWgbY5kd3Kyb4LheIlwdiCrbnP1ZoF1\WRiZn;yJFYh\GG7czDwdolweiC2bzDbN2hefGi7bXnkbY5mKGGmZHn0bY9vKG2nYYP1doVlKGGodHXyJFE5KGi{czDifUBtcXG3aXSgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiSVO1NEA:KDBwMEW0JO69VS5?	MlnyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|NEe4NFQoRjJ\|M{S3PFA1RC:jPh?=
MT4	NVjWSmg3SW62aY\pdoFtKGG\|c3H5		MkX6OEBl[Xm\|	M3r1UGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiM1KgbY5n\WO2ZXSgbY4hcHWvYX6gUXQ1KGOnbHzzJINwcW6oZXP0[YQhf2m2aDDIWGxXOSCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hfmm{dYOtbY5lfWOnZDDjfZRweGG2aH;n[Y5q[2m2eTDh[pRmeiB2IHThfZMh[nliTWTUJIF{e2G7LDDFR\|UxKD1iMD60OUDPxE1w	NF[3V289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0PVg5OCd-MkO4OFk5QDB:L3G+
A2780Adr	NG\WfpBHfW6ldHnvckBie3OjeR?=		MWizNEBucW6\|	MY\Jcohq[mm2aX;uJI9nKHBvZ3z5Z49xem:2ZXnuJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKGi3bXHuJGEzPzhyQXTyJINmdGy\|IHHzd4V{e2WmIHHzJINidGOnaX6tRW0h[WOldX31cIF1cW:wIIDy[Ylv[3WkYYTl[EBnd3JiM{CgcYlveyCkZX\vdoUh[2GuY3Xpck1CVSCjZHTpeIlwdiCvZXHzeZJm\CC3cDD0c{A6OCCvaX7zJIJ6KG[udX;y[ZNk\W6lZTDhd5NigSxiSVO1NEA:KDBwOUmg{txONg>?	NGe3bXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i1NVEyPCd-MkO4OVEyOTR:L3G+
2008	MXrGeY5kfGmxbjDhd5NigQ>?		MYOzNEBucW6\|	NX3URlM3UW6qaXLpeIlwdiCxZjDNVnAyKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIHj1cYFvKDJyMEigZ4VtdHNiYYPz[ZN{\WRiYYOgZ4Ft[2Wrbj3BUUBi[2O3bYXsZZRqd25icILlbY5kfWKjdHXkJIZweiB\|MDDtbY5{KGKnZn;y[UBk[WylZXnuMWFOKGGmZHn0bY9vKG2nYYP1doVlKHWyIITvJFkxKG2rboOgZpkh\my3b4Lld4NmdmOnIHHzd4F6NCCLQ{WwJF0hOi56MTFOwG0v	M17xfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEWxNVE1Lz5{M{i1NVEyPDxxYU6=
Jurkat T	M{TLOGZ2dmO2aX;uJIF{e2G7		NFfqcIM{OCCvaX7z	NUDYe4piUW6qaXLpeIlwdiCxZjDOSmFVKGGldHn2ZZRqd25iaX6gVG1CN2mxbn;tfYNqdi2\|dHnteYxifGWmIHj1cYFvKEq3cnvheEBVKGOnbHzzJIlv[3WkYYTl[EBnd3JiM{CgcYlveyCycnnvdkB1dyCSTVGvbY9vd227Y3nuJJN1cW23bHH0bY9vKG2nYYP1doVlKGGodHXyJFUhcHK\|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiSVO1NEA:KDBwMECxOEDPxE1w	NEfENpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m2OFk6OSd-MkO5OlQ6QTF:L3G+
MDA435/LCC6MDR	NHfy[4tHfW6ldHnvckBie3OjeR?=			NWj6e2M{VW:mdXzheIlwdiCxZjDwMYdxKCi3bnvuc5dvKG:{aXfpckkhfHKjboPm[YN1\WRiaX6gbJVu[W5iTVTBOFM2N0yFQ{\NSHIh[2WubIOgZZN{\XO\|ZXSgZZMhemW4ZYLzZYwhd2ZicHHjcIl1[XinbDDy[ZNqe3SjbnPlMEBGSzVyIE2gNE4xOzJizszNMi=>	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF5MUS3PEc,OjRzN{G0O\|g9N2F-
MDA435/LCC6	M4\jdWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NYLScZI3OyCmYYnz	MULDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGE1OzVxTFPDOkBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjCzJIRigXNiYomgUXRUKGG\|c3H5MEBKSzVyIE2gNk45KM7:TT6=	MnXNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzN{G0O\|goRjJ2MUexOFc5RC:jPh?=
MDA435/LCC6MDR	MWfDfZRwfG:6aXPpeJkh[XO\|YYm=		NIrGO\|Y{KGSjeYO=	NFm0OWFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEF2M{WvUGNEPk2GUjDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB\|IHThfZMh[nliTWTTJIF{e2G7LDDJR\|UxKD1iOD6zJO69VS5?	NETvdHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG3NVQ4QCd-MkSxO\|E1Pzh:L3G+
L929	M3HlTWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NYfo[mx3OyCmYYnz	Mn;3R5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgUFkzQSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA{KGSjeYOgZpkhVVSVIHHzd4F6NCCLQ{WwJF0hOzNwOTFOwG0v	MkXXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzN{G0O\|goRjJ2MUexOFc5RC:jPh?=
A2780adr	M3y0OGZ2dmO2aX;uJIF{e2G7		NWHlZoF4fXBidH:gPVAhdWmwcx?=	MUjJcohq[mm2aX;uJI9nKE2GUkGgbY4hcHWvYX6g[I95d3K3YnnjbY4uemW\|aYP0ZY51KEF{N{iwZYRzKGOnbHzzJIF{e2W\|c3XkJIF{KEOjbHPlbY4hSU1iYXPjeY12dGG2aX;uJJRz\WG2ZXSgN\|AhdWmwczDi[YZwemViQ3HsZ4VqdiCDTTDh[IRqfGmxbjDt[YF{fXKnZDD1dEB1dyB7MDDtbY5{KGK7IH\seY9z\XOlZX7j[UBie3OjeTygTWM2OCB;IECuPVIh\|ryPLh?=	NH2zOJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG4OFIyOyd-MkSxPFQzOTN:L3G+
2008	NULpbIVKTnWwY4Tpc44h[XO\|YYm=		NVPSV2ZwfXBidH:gPVAhdWmwcx?=	MWTJcohq[mm2aX;uJI9nKE2UUEGgbY4hcHWvYX6gNlAxQCClZXzsd{Bie3Onc4Pl[EBieyCFYXzj[YlvKEGPIHHjZ5VufWyjdHnvckB1emWjdHXkJFMxKG2rboOgZoVnd3KnIFPhcINmcW5iQV2gZYRlcXSrb36gcYVie3W{ZXSgeZAhfG9iOUCgcYlveyCkeTDmcJVwemW\|Y3XuZ4Uh[XO\|YYmsJGlEPTBiPTCyMlch\|ryPLh?=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF6NEKxN{c,OjRzOESyNVM9N2F-
Saos2	MVvGeY5kfGmxbjDhd5NigQ>?	NUmxPJBJPSC3TR?=	NF3VZWQ{KGi{cx?=	MUjJcohq[mm2aX;uJI9nKHBvZ4CgbY4h\G:6b4L1ZolkcW5vcnXzbZN1[W62IHj1cYFvKFOjb4OyJINmdGy\|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGSxeH;yeYJq[2mwIIXweIFs\SCjdDC1JJVOKGGodHXyJFMhcHK\|IHL5JIZtd3diY4n0c41mfHKrYzDhcoFtgXOrcz6=	Mmj0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5MkC0OVIoRjJ2N{KwOFUzRC:jPh?=
Saos2	MnPESpVv[3Srb36gZZN{[Xl?	MmXkOUB2VQ>?	NVfQZ3Q6OiCqcoO=	M1TCPWlvcGmkaYTpc44hd2ZicD3ndEBqdiCmb4jvdpVjcWOrbj3y[ZNqe3SjboSgbJVu[W5iU3Hvd\|Ih[2WubIOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iaX70doFk\WyudXzhdkBld3ixcoXibYNqdiC{ZYTlcpRqd25iYYSgOUB2VSCjZoTldkAzKGi{czDifUBndG:5IHP5eI9u\XS{aXOgZY5idHm\|aYOu	Mn\rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5MkC0OVIoRjJ2N{KwOFUzRC:jPh?=
Saos2	MVnGeY5kfGmxbjDhd5NigQ>?	M{C2V\|UhfU1?	NF36Z3kzKHSxIEOgbJJ{	NIT0bXJKdmirYnn0bY9vKG:oIICt[5AhcW5iZH;4c5J2[mmlaX6tdoV{cXO2YX70JIh2dWGwIGPhc5MzKGOnbHzzJIF{e2W\|c3XkJIF{KGmwdILhZ4VtdHWuYYKg[I95d3K3YnnjbY4h\Gm\|dILpZpV1cW:wIHnuJI52[2ynaTDheEA2KHWPIHHmeIVzKDJidH:gN{BpenNiYomgcIF{\XJic3Phco5qdmdiY3;u[o9k[WxibXnjdo9{[2:yaXOgZY5idHm\|aYOu	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd{MES1Nkc,OjR5MkC0OVI9N2F-
mouse	MXfGeY5kfGmxbjDhd5NigQ>?			NWHMNnJ[UW6qaXLpeIlwdiCxZjDoeY1idiCPRGKxJIV5eHKnc4Pl[EBqdiCvb4Xz[UBNPTF5ODDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBqdnS{YXPlcIx2dGG{IHHjZ5VufWyjdHnvckBw\iC{aH;kZY1qdmViMUKzJIJ6KE[DQ2PDZYxq[nW{IH\sc5ch[3m2b33leJJ6NCCLQ{WwJF0hOC54NzFOwG0v	Mn3VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MECyNlYoRjJ2OUCwNlI3RC:jPh?=
A2780	MnHhSpVv[3Srb36gZZN{[Xl?	NHfWUWY2KHWP	NYi5RoNYPDBibXnudy=>	MV;Jcohq[mm2aX;uJI9nKFCpcD3t[YRq[XSnZDDkdpVoKGWoZnz1fEBqdiCjZILpZY16[2mwLYLld4l{fGGwdDDoeY1idiCDMke4NEBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCrboTyZYNmdGy3bHHyJIFlemmjbYnjbY4hdGW4ZXygZZQhPSC3TTDh[pRmeiB2MDDtbY5{KGK7IH\sc5ch[3m2b33leJJ6KGGwYXz5d4l{Ng>?	NEnGbVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFMzOyd-MkS5NFA{OjN:L3G+
A2780	NWDIdIpHTnWwY4Tpc44h[XO\|YYm=	NUHVUXFVPSC3TR?=	NYHGcVJLOSCqch?=	MoLNTY5pcWKrdHnvckBw\iCSZ4CtcYVlcWG2ZXSg[JJ2\yCnZn\seZghcW5iYXTybYFugWOrbj3y[ZNqe3SjboSgbJVu[W5iQUK3PFAh[2WubIOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iYXTybYFugWOrbjD1dJRic2ViYYSgOUB2VSCjZoTldkAyKGi{IHL5JIZtd3diY4n0c41mfHK7IHHuZYx6e2m\|Lh?=	M2LI[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwN\|I{Lz5{NEmwNFMzOzxxYU6=
A2780	M1zXO2Z2dmO2aX;uJIF{e2G7	NXzEPXJNPSC3TR?=	NX60bJR5QCCqcoO=	NHfWXlhKdmirYnn0bY9vKG:oIGDndE1u\WSrYYTl[EBlenWpIHXm[ox2gCCrbjDh[JJq[W27Y3nuMZJme2m\|dHHueEBpfW2jbjDBNlc5OCClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDh[JJq[W27Y3nuJJVxfGGtZTDheEA2KHWPIHHmeIVzKDhiaILzJIJ6KG[ub4egZ5l1d22ndIL5JIFv[Wy7c3nzMi=>	Mlm3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MECzNlMoRjJ2OUCwN\|I{RC:jPh?=
T-cells	MkTJRY51cWmwZnzhcY1ifG:{eTDhd5NigQ>?	NILoV3QxNjBzIITvJFExOCCwTR?=	MWeyJIRigXN?	NGG3ZolCdnSraX7mcIFudWG2b4L5JIFkfGm4aYT5JIlvKEyOT{GxPEBVS1JidILhcpNo\W6rYzDtc5V{\SCLTD2yMYNwdXCndHXueEBETDRvcH;zbZRqfmViVDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEyOTzCoNVkxKHSxIEKwOUkucW6mdXPl[EBKVC1{IIDyc4R2[3Srb36gZZQhOC5yMTD0c{AyODBibl2g[o9zKDJiZHH5d{BjgSCobH;3JIN6fG:vZYTybYMh[W6jbInzbZMv	M3LK[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwPFY3Lz5{NEmwNFg3PjxxYU6=
Th17	MWfBcpRqcW6obHHtcYF1d3K7IHHzd4F6	M3PrUlExKHSxIEGwNEBvVQ>?	NXPoT2k2OiCmYYnz	NX6wVJRySW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCOTF:xNVghXEOUIITyZY5{\2WwaXOgcY92e2ViVHixO{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFnMMVE4KHC{b3T1Z5Rqd25iYYSgNVAhfG9iMUCwJI5OKG[xcjCyJIRigXNiYomg[oxwfyCleYTvcYV1emmlIHHuZYx6e2m\|Lh?=	MoLzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC4OlYoRjJ2OUCwPFY3RC:jPh?=
Th1	MYTBcpRqcW6obHHtcYF1d3K7IHHzd4F6	MWexNFAhdk1?	MVWyJIRigXN?	MlnvRY51cWmwZnzhcY1ifG:{eTDhZ5Rqfmm2eTDpckBNVE9zMUigWGNTKHS{YX7z[4VvcWNibX;1d4UhXGhzIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhUU[QLXfhcY1iKHC{b3T1Z5Rqd25iYYSgNVAxKG6PIH\vdkAzKGSjeYOgZpkh\myxdzDjfZRwdWW2cnnjJIFv[Wy7c3nzMi=>	MnO0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC4OlYoRjJ2OUCwPFY3RC:jPh?=
NCI/ADR-RES	NEHYOHBHfW6ldHnvckBie3OjeR?=		NVPyS\|lZOjBibXnudy=>	MV3Jcohq[mm2aX;uJI9nKGi3bXHuJHAu\2y7Y3;wdo91\WmwIHX4dJJme3OnZDDpckBPS0lxQVTSMXJGWyClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gZ4Ft[2Wrbj3BUUB1emGwc4DvdpQh[W[2ZYKgNlAhdWmwczDifUBndHWxcnXzZ4Vv[2ViYYPzZZkv	NWXLTplQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5PVIyPTNpPkK0PVkzOTV\|PD;hQi=>
A2780adr	NVmxbnY3TnWwY4Tpc44h[XO\|YYm=		NV6ydoVmQTBibXnudy=>	NWTQXZc2UW6qaXLpeIlwdiCxZjDBRmNDOSCrbjDoeY1idiCDMke4NIFleiClZXzsd{BxemVvaX7jeYJifGWmIH\vdkA{OCCvaX7zJIZwdGyxd3XkJIJ6KGOjbHPlbY4hSU1iYXTkbZRqd25iYX7kJIZ2enSqZYKgbY5kfWKjdHXkJIZweiB4MDDtbY5{KGK7IHPhcINmcW5iQV2gZZN{[XluIFnDOVAhRSByLkmxPUDPxE1w	NVq2UVlWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4OVU5QTVpPkK1PFU2QDl3PD;hQi=>
T spleen cells	M4X1cmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NYDH[2tPPzJiaILz	MYnDfZRwfG:6aXPpeJkh[WejaX7zeEBKS1JibX;1d4UhXCC\|cHzl[Y4h[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFEh\|ryPLh?=	Mli2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkSyOlYoRjJ4NU[0NlY3RC:jPh?=
B spleen cells	NFLXNZpEgXSxdH;4bYNqfHliYYPzZZk>		M{\vOVczKGi{cx?=	M{iyT2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KEmFUjDtc5V{\SCEIIPwcIVmdiClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxicILvcIln\XKjdHnvckBi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4xPCEQvF2u	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4NEK2Okc,OjZ3NkSyOlY9N2F-
RD	NXfsOHUySW62aY\pdoFtKGG\|c3H5		MmCzNlQhcHK\|	MWrBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDFWlcyKGmwZnXjeIVlKGmwIGLEJINmdGy\|IHHmeIVzKDJ2IHjyd{BjgSCudXPp[oVz[XOnIHHzd4F6NCCHQ{WwJF0hOy54NjFOwG0v	M{DLO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[0NlY3Lz5{NkW2OFI3PjxxYU6=
mouse lymph node cells	NHPKUVJHfW6ldHnvckBie3OjeR?=			MnXHTY5pcWKrdHnvckBw\iCSSUPLMYdidW2jIHnuJI1wfXOnIHz5cZBpKG6xZHWgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCFb37BMZN1cW23bHH0[YQhXCClZXzsJJBzd2yrZnXyZZRqd25uIFnDOVAhRSByLkW3JO69VS5?	MmC1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5MkCxOVQoRjJ4N{KwNVU1RC:jPh?=
CD1	NX\tWYNqTnWwY4Tpc44h[XO\|YYm=	NFfOb2kxNjFidH:gNVAhfU1?	NUjYbldwOzBibXnudy=>	MYDJcohq[mm2aX;uJI9nKHSjdYLvcIl1cG:laH;sZZRmKGGlaXSgN{1{fWyoYYTlMYlv\HWlZXSgcoVkem:\|aYOgbY4hS0RzIH3veZNmKHCjbnPy[YF1cWNiYXPpcoFzKGOnbHzzJIF1KDBwMTD0c{AyOCC3TTDh[pRmeiB\|MDDtbY5{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdiYnHz[YQh[2:wZn;jZYwhdWmlcn;zZ49xcWNiYX7hcJl{cXNw	Mn7tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7NUCzPVIoRjJ4OUWwN\|kzRC:jPh?=
A2780/ADR	NGXycIRHfW6ldHnvckBie3OjeR?=		NYP2U21JOzBibXnudy=>	MnG5TY5pcWKrdHnvckBw\iCDQlPCNUBqdiCqdX3hckBCOjd6MD;BSHIh[2WubIOgbY5kfWKjdHXkJIZweiB\|MDDtbY5{KG2nYYP1doVlKHWyIITvJFM3ODBic3Xjd{B4cXSqIITpcYUhcW62ZYL2ZYx{KG:oIE[wJJNm[3NiYomgZ4Ft[2WrbjDhZ4N2dXWuYYTpc44h[XO\|YYmsJGlEPTBiPTCxMlQyKM7:TT6=	M2LwWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUCwNFM{Lz5{N{GwNFA{OzxxYU6=
A2780/ADR	MV\DfZRwfG:6aXPpeJkh[XO\|YYm=		NFfZUWY4OiCqcoO=	NITJRnpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCOjd6MD;BSHIh[2WubIOgc5ZmemW6cILld5NqdmdiQVLDRlEh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFfJOVAhRSB6Lk[zJO69VS5?	Ml[wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzMECwN\|MoRjJ5MUCwNFM{RC:jPh?=
A2780	MX7DfZRwfG:6aXPpeJkh[XO\|YYm=		NWPkXHV6PzJiaILz	MWXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBNlc5OCClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiR1m1NEA:KDhwOUSg{txONg>?	MmS1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzMECwN\|MoRjJ5MUCwNFM{RC:jPh?=
MDCK2	NED3d2xHfW6ldHnvckBie3OjeR?=			MXnJcohq[mm2aX;uJI9nKEGEQ1OyJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKE2GQ1uyJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3HsZ4Vqdi2DTTDl[oZtfXhibXXhd5Vz\WRiYX\0[ZIhOzBibXnud{BqdiCycnXz[Y5k\SCxZjDBRmNDOSCrbnjpZol1d3JiR1[xNlA6OThiYX7kJGFDS0NzIHnubIljcXSxcjDNT{02PzFiYomg[oxwfyCleYTvcYV1enluIFnDOVAhRSB{NT62JO69VS5?	NWXPWZRERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkezPVM6PDlpPkK3N\|k{QTR7PD;hQi=>
Flp-InTM-293	M2e0c2Z2dmO2aX;uJIF{e2G7	NF30c20zPSC3TR?=	M4nJWFMxKG2rboO=	NVLNPFFtUW6qaXLpeIlwdiCxZjDBRmNEOiBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDoeY1idiCIbICtTY5VVS1{OUOgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClYXzj[YlvNUGPIHXm[ox2gCCjdDCyOUB2VSCvZXHzeZJm\CCjZoTldkA{OCCvaX7zJIlvKHC{ZYPlcoNmKG:oIFHCR2IyKGmwaHnibZRweiCJRkGyNFkyQCCjbnSgRWJESzFiaX7obYJqfG:{IF3LMVU4OSCkeTDmcI94KGO7dH;t[ZRzgS5?	NXW3[YdORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkezPVM6PDlpPkK3N\|k{QTR7PD;hQi=>
hamster BHK21	Mn7PSpVv[3Srb36gZZN{[Xl?	MV[yOUB2VQ>?	NFPV[3A{OCCvaX7z	NEHVeHBKdmirYnn0bY9vKG:oIHj1cYFvKEGEQ1OxJIV5eHKnc4Pl[EBqdiCqYX3zeIVzKEKKS{KxJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3HsZ4Vqdi2DTTDl[oZtfXhiYYSgNlUhfU1ibXXhd5Vz\WRiYX\0[ZIhOzBibXnud{BjgSCobH;3JIN6fG:vZYTyfU4>	NW\OTGlrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkezPVM6PDlpPkK3N\|k{QTR7PD;hQi=>
MDCK2	MlLISpVv[3Srb36gZZN{[Xl?	M3Xnb\|I2KHWP	MnLaN\|AhdWmwcx?=	NW\OVFNlUW6qaXLpeIlwdiCxZjDBRmNEOiBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDNSGNMOiClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINidGOnaX6tRW0h\W[obIX4JIF1KDJ3IIXNJI1m[XO3cnXkJIFnfGW{IEOwJI1qdnNiaX6gdJJme2WwY3Wgc4YhSUKFQkGgbY5pcWKrdH;yJGdHOTJyOUG4JIFv\CCDQlPDNUBqdmirYnn0c5IhVUtvNUexJIJ6KG[ub4egZ5l1d22ndIL5Mi=>	MkHVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd\|OUO5OFkoRjJ5M{mzPVQ6RC:jPh?=
NH3T3	M4nIPWZ2dmO2aX;uJIF{e2G7	MlzUNk42KHWP	NHTPO\|E{OCCvaX7z	M4LvPGlvcGmkaYTpc44hd2ZiaIXtZY4hSUKFQkGg[ZhxemW\|c3XkJIlvKG2xdYPlJG5JO1R\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh[2GuY3Xpck1CVSCnZn\seZgh[XRiMj61JJVOKG2nYYP1doVlKGGodHXyJFMxKG2rboOgZpkh\myxdzDjfZRwdWW2comu	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzN7M{m0PUc,Ojd\|OUO5OFk9N2F-
Jurkat T	NVTJWGVPUW2vdX7vd5VxeHKnc4PpeoUh[XO\|YYm=		NEPRPG8yOyCqcoO=	MmW2TY1ufW6xc4XwdJJme3OrdnWgZYN1cX[rdImgbY4hcHWvYX6gVG1CN2mxbn;tfYNqdiC\|dHnteYxifGWmIFr1dotifCCWIHPlcIx{KGG\|c3Xzd4VlKGG\|IIP1dJBz\XO\|aX;uJI9nKEmOMjDwdo9lfWO2aX;uJJBz\XS{ZXH0[YQhf2m2aDDj[YxteyCob3zsc5dm\CCkeTDQUWEwcW:wb335Z4lvKHO2aX31cIF1cW:wIH3lZZN2emWmIHHmeIVzKDF\|IHjyd{BjgSCHTFnTRUwhUUN3MDC9JFAvODFzIN88UU4>	Ml3SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd4NEezO\|AoRjJ5NkS3N\|cxRC:jPh?=
A2780/ADR	M1nTbmZ2dmO2aX;uJIF{e2G7		MmnrN\|AhdWmwcx?=	NWfBSJVDUW6qaXLpeIlwdiCxZjDBRmNDOSCrbjDoeY1idiCDMke4NE9CTFJiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINidGOrZX6tRW0h\W[obIX4JJBz\WmwY4XiZZRm\CCob4KgN\|AhdWmwczDmc4xtd3enZDDifUBk[WylaXXuMWFOKGGmZHn0bY9vKG2nYYP1doVlKGmvbXXkbYF1\Wy7IHH0JFYxKHOnYzD0bY1mKGmwdHXyeoFtKG[xcjC2NEBucW6\|IHL5JIZtfW:{ZYPj[Y5k\SCjc4PhfUwhUUN3MDC9JFEvOjFizszNMi=>	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzZ5NkS2PUc,Ojd4N{[0Olk9N2F-
MDA435/LCC6MDR	MVfGeY5kfGmxbjDhd5NigQ>?	NX7pWlRtOSC3TR?=	M{G0TlUh\GG7cx?=	NXf4OFZEUW6qaXLpeIlwdiCxZjDQMYdxKGmwIHj1cYFvKE2GQUSzOU9NS0N4TVTSJINmdGy\|IHHzd4V{e2WmIHHzJJBwfGWwdHnheIlwdiCxZjDwZYNtcXSjeHXsMYlv\HWlZXSgZ5l1d3SxeHnjbZR6KGK7IH3lZZN2emmwZzDwZYNtcXSjeHXsJGlEPTBiYYSgNUB2VSCvZXHzeZJm\CCjZoTldkA2KGSjeYOgZpkhS2WubDDUbZRmeiB7NjDBdZVmd3W\|IHHzd4F6KCiUdnKgQUAyOzlwMzCrM{0hPy53IH7NLUwhUUN3MDC9JFAvODBzODFOwG0v	Mn\aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5NUCxPVcoRjJ5N{WwNVk4RC:jPh?=
K562R	MULGeY5kfGmxbjDhd5NigQ>?	M3TD[FUhfU1?	NEfMfIkyKGi{	Mn\FTY5pcWKrdHnvckBw\iCSLXfwJIlvKGSxeH;yeYJq[2mwLYLld4l{fGGwdDDoeY1idiCNNU[yVkBk\WyuczDhd5Nme3OnZDDhd{BzcG:mYX3pcoUh\W[obIX4JIJ6KG2nYYP1dolv\yC{YYTpc{Bw\iCvZXHuJIZtfW:{ZYPj[Y5k\SCrboTlcpNqfHliaX6gdJJme2WwY3WgZY5lKGGkc3XuZ4Uhd2ZiY3;tdI92dmRiYYSgOUB2VSCrbnP1ZoF1\WRiZn;yJFEhcHJiYomg[oxwfyCleYTvcYV1enlw	M4DufVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{WzOFgxLz5{N{e1N\|Q5ODxxYU6=
HuH7	NGTWTWFCdnSrdnnyZYwh[XO\|YYm=		NVLjVVFOPzJiaILz	M4HBWGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhEXiCpZX7veJlx\SBzYjDDc44yKGmwZnXjeIVlKGmwIHj1cYFvKEi3SEegZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygSWM2OCB;IECuNVch\|ryPLh?=	Mli1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyN{W1PVEoRjJ6MEe1OVkyRC:jPh?=
HepaRG	NYfrcGhySW62aY\pdoFtKGG\|c3H5		NVPYNIlEOTZiaILz	MU\BcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDIRnYhcW6oZXP0[YQhcW5iaIXtZY4hUGWyYWLHJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiC4aYLhcEBqdm[nY4Tpc44h[W[2ZYKgNVYhcHK\|LDDJR\|UxKD1iMD6yJO69VS5?	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDN6M{K3OEc,Ojh\|OEOyO\|Q9N2F-
replicon 2A cells	M{e3eGZ2dmO2aX;uJIF{e2G7		NEjOR5I4OiCqcoO=	MUfJcohq[mm2aX;uJI9nKG2WT2Kgd4lodmGuaX7nJJBifGi5YYmgbY4hMHWwa37ve44hd3KrZ3nuLUBqdiC\|dXKt[4Vvd22rYzDy[ZBtcWOxbjCyRUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5icHjvd5Bpd3K7bHH0[YQhenC\|NjDwdo91\WmwIHzleoVteyC3cDD0c{A1ODBibl2gZYZ1\XJiN{KgbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpd{4>	NWjGU2xZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0OFIzPTZpPkK4OFQzOjV4PD;hQi=>
A2780adr	Mn[wSpVv[3Srb36gZZN{[Xl?		M2jEeFMxKG2rboO=	MV7Jcohq[mm2aX;uJI9nKEGEQ1KxJIlvKGi3bXHuJGEzPzhyYXTyJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClYXzj[YlvKEGPIHzleoVteyCycnXpcoN2[mG2ZXSg[o9zKDNyIH3pcpMh\m:ubH;3[YQh[nliY3HsZ4VqdiCDTTDh[IRqfGmxbjDt[YF{fXKnZDDpcY1m\GmjdHXsfUBifCB4MDDz[YMhfGmvZTDpcpRmen[jbDDmc5IhPjBibXnud{BjgSCobIXvdoV{[2WwY3WgZZN{[XluIFnDOVAhRSBzLkKxJO69VS5?	M2XHcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEexOlU3Lz5{OES3NVY2PjxxYU6=
H69AR	M3vHU2Z2dmO2aX;uJIF{e2G7		MY[zNEBucW6\|	MXzJcohq[mm2aX;uJI9nKEGEQ1OxJIlvKGi3bXHuJGg3QUGUIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBk[WylZXnuJGFOKGyndnXsd{BxemWrbnP1ZoF1\WRiZn;yJFMxKG2rboOg[o9tdG:5ZXSgZpkh[2GuY3XpckBCVSCjZHTpeIlwdiCvZXHzeZJm\CCrbX3l[IlifGWueTDheEA3OCC\|ZXOgeIlu\SCrboTldpZidCCob4KgOlAhdWmwczDifUBndHWxcnXzZ4Vv[2ViYYPzZZktKEmFNUCgQUAzNjl5IN88UU4>	MnK3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2N{G2OVYoRjJ6NEexOlU3RC:jPh?=
A2780/ADR	MXPGeY5kfGmxbjDhd5NigQ>?		NFnHWm4{OCCvaX7z	MXPJcohq[mm2aX;uJI9nKEGEQ1KxJIlvKGi3bXHuJGEzPzhyL1HEVkBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3HsZ4Vqdi2DTTDl[oZtfXhicILlbY5kfWKjdHXkJIZweiB\|MDDtbY5{KG[xbHzve4VlKGK7IHPhcINmcW5vQV2gZYRlcXSrb36gcYVie3W{ZXSgZZQhPjBic3Xjd{BqdnSnco\hcEBnd3JiNkCgcYlveyCkeTDmcJVwemW\|Y3XuZ4Uh[XO\|YYmsJGlEPTBiPTCxMlIyKM7:TT6=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh2MUWxN{c,Ojh6NEG1NVM9N2F-
H69AR	NYLRdo5NTnWwY4Tpc44h[XO\|YYm=		NUnCZ257OzBibXnudy=>	MXHJcohq[mm2aX;uJI9nKEGEQ1OxJIlvKGi3bXHuJGg3QUGUIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBk[WylZXnuMWFOKGWoZnz1fEBxemWrbnP1ZoF1\WRiZn;yJFMxKG2rboOg[o9tdG:5ZXSgZpkh[2GuY3Xpck1CVSCjZHTpeIlwdiCvZXHzeZJm\CCjdDC2NEB{\WO\|IHnueIVzfmGuIH\vdkA3OCCvaX7zJIJ6KG[udX;y[ZNk\W6lZTDhd5NigSxiSVO1NEA:KDNwNUOg{txONg>?	M17aNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OESxOVE{Lz5{OEi0NVUyOzxxYU6=
A673	MVvxTHRUKGG\|c3H5			MULxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtey5?	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Saos-2	NX;BW3R7eUiWUzDhd5NigQ>?			NIjIeHFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzzMi=>	NXTxZmx1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37	NFTCPI1yUFSVIHHzd4F6			MlPadWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUO3JINmdGy\|Lh?=	MkSyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
RD	NHTqWo5yUFSVIHHzd4F6			NYH0WFBKeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLEJINmdGy\|Lh?=	NXHxWHN4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R)	M{fOVpFJXFNiYYPzZZk>			MlHtdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy\|Lh?=	NF[xTnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB1643	NITJfmlyUFSVIHHzd4F6			NFfNR5hyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzzMi=>	NUHLRpRWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50	NV7jOXo6eUiWUzDhd5NigQ>?			NH:xeY1yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzzMi=>	M{[2OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	MXHxTHRUKGG\|c3H5			M1K5TZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaESxJINmdGy\|Lh?=	M{\GUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh30	NVHGUZdQeUiWUzDhd5NigQ>?			NXnIT2NoeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWmh\|MDDj[Yxtey5?	NWjYPIdbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41	NX7wfoJQeUiWUzDhd5NigQ>?			NFnhOlZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDRzIHPlcIx{Ng>?	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	M1zKRZFJXFNiYYPzZZk>			NWHLR2g6eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJMv	NUOz[phTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18	M2DiTZFJXFNiYYPzZZk>			MYrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmhzODDj[Yxtey5?	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	M{fSZ5FJXFNiYYPzZZk>			MWTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTT{1PNU2FIHPlcIx{Ng>?	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
TC32	NHvoPGVyUFSVIHHzd4F6			Mlq3dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgWGM{OiClZXzsd{4>	NHHyOYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
C57BL/6 mouse lymph node cells	M{K1XmludXWwb4P1dJBz\XO\|aY\lJIF{e2G7		MljvNlQhcHK\|	NUewXoQ{UW2vdX7vd5VxeHKnc4PpeoUh[WO2aY\peJkhcW5iQ{W3RmwwPiCvb4Xz[UBtgW2yaDDuc4RmKGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlUh\|ryPLh?=	Mme4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl6N{G4OFQoRjJ7OEexPFQ1RC:jPh?=
HuH7	M3nuZ2FvfGm4aYLhcEBie3OjeR?=		NFrI[lI{KGSjeYO=	NWe0[ZhKSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEOYIHflco91gXCnIELhJIlv\mWldHXkJIlvKGi3bXHuJGh2UDdiY3XscJMh[W[2ZYKgN{Bl[Xm\|IHL5JIR2[WxvZ3zvJIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NEA:KDBwN{ezJO69VS5?	NHfiRWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEC3OFc6PSd-M{CwO\|Q4QTV:L3G+
MT4	MWnDfZRwfG:6aXPpeJkh[XO\|YYm=		MXS0JJRwKDViZHH5dy=>	M1\YOWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1VPCClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPCC2bzC1JIRigXNiYomgZ4VtdC22aYTldkBodG9iYYPzZZktKEOFNUCgQUA2NjZyODFOwG0v	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB5NEe5OUc,OzByN{S3PVU9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Phospho-AKT1 / AKT1 / PTEN / Phospho-BAD / BAD / Procaspase-3; PubMed: 12644839 Br J Cancer. Western blot analysis of phospho-AKT1, AKT1, PTEN, phospho-BAD, BAD and procaspase-3 expression in HepG2 cells treated with cyclosporin A (CA, 10 μm) and/or Taxol (Tx, 0.1 μm). Cyp-D / AIF / β-actin; PubMed: 29328412 Mol Med Rep. Western blot analysis of protein expression levels of Cyp-D and AIF in the spinal cord. P<0.05, P<0.01, **P<0.001. SCI, spinal cord injury; CsA, cyclosporin A; Cyp-D, cyclophilin-D; AIF, apoptosis-inducing factor. IL-8 / MCP-1; PubMed: 9602633 Br J Ophthalmol. Representative northern blots revealing the effects of dexamethasone (DEX) and cyclosporin A (CSA) on rIL-1β induced (20 ng/ml) IL-8 and MCP-1 mRNA expression in human orbital fibroblasts at 24 hours. Equivalent total cellular RNA loading per lane is demonstrated by the electrophoretic profile (below) of 18s and 28s rRNA in all lanes, except the high dose CSA lane in which cell death occurred from cyclosporin toxicity. Actin / Smac; PubMed: 12427831 J Neurosci. Regulation of Aβ25–35-induced Smac release from mitochondria in CECs. CECs were treated with 25 μm Aβ25–35 in the presence of cyclosporin A (B) at indicated concentrations, and cytosolic fractions were analyzed by immunoblotting with anti-Smac antibody. Cyclosporin A inhibited Smac release. β-actin / FIPV-N; PubMed: 22546085 Vet Res. Cyclosporin A suppresses FIPV replication in fcwf-4 cells. (B) Western blots of cells incubated with various concentrations of CsA. Lanes show total cellular proteins resolved by electrophoresis. Effects of CsA were assessed using monoclonal anti-FIPV-N and anti-β-actin primary antibodies.	12644839 29328412 9602633 12427831 22546085
Growth inhibition assay	NPC death; PubMed: 20181586 J Neurosci. Cyclosporin A (CsA) enhanced NPC survival. A, Significantly fewer cyclosporin A-treated NPCs die over 3 d compared with control NPCs (p < 0.05).	20181586
IHC	Th22 / Th17 / Th1 / M1 / Th2; PubMed: 30916387 Clin Exp Immunol. (a) Percentage of pro‐ and anti‐inflammatory cells in graft biopsies from kidney transplant recipients (KTR) under belatacept or cyclosporin A treatment. Interleukin (IL)‐22‐, CD4/IL‐17A‐, CD4/interferon (IFN)‐γ‐, CD16/tumor necrosis factor (TNF)‐α‐ and CD4/IL‐4‐expressing cells in graft biopsies. Belatacept: n = 23 biopsies and cyclosporin A: n = 10 biopsies. Arrows depict double immunoreactive cells (in burgundy). Arrowhead shows a CD4+ T cell (in brown). Results are expressed as median (black line), mean (red line), and 5th/95th percentiles. Statistical analysis: one‐way analysis of variance; Dunn’s method. Tregs / Bregs / pDCs / M2; PubMed: 30916387 Clin Exp Immunol. (b) Percentage of regulatory cells in graft biopsies from kidney transplant recipients (KTR) under belatacept or cyclosporin A treatment. CD25/forkhead box protein 3 (FoxP3)‐, CD20/IL‐10‐, CD123/L‐kynurenine‐ and CD163/IL‐10‐expressing cells in graft biopsies. Arrows depict double immunoreactive cells (in burgundy). Arrowhead shows a CD25+ T cell (in pink). Belatacept: n = 23 biopsies and cyclosporin A: n = 10 biopsies. Results are expressed as median (black line), mean (red line), and 5th/95th percentiles. Statistical analysis: one‐way analysis of variance; Dunn’s method. Ki 67 / Fas-FasL; PubMed: 30916387 Clin Exp Immunol. (c) Percentage of senescent, apoptotic and proliferating cells in graft biopsies from KTR under belatacept or cyclosporin A treatment. Ki‐67‐, p16INK4α‐ and FAS/FASL‐expressing cells in graft biopsies. Photomicrographs on the left shows the expression of Ki67. Photomicrographs on the right depict the apoptotic cells. Belatacept: n = 23 biopsies and cyclosporin A: n = 10 biopsies. Results are expressed as median (black line), mean (red line) and 5th/95th percentiles. Statistical analysis: one‐way analysis of variance; Dunn’s method. IFN-γ / TNF-α; PubMed: 10931158 Clin Exp Immunol. Effect of cyclosporin A (CsA) on expression of IFN-γ and tumour necrosis factor-alpha (TNF-α). (a) Renal expression of IFN-γ in a rat with chronic serum sickness (CSS). (b) IFN-γ in a rat treated with CsA. (c) TNF-α in rat with CSS. (d) TNF-α expression in a CsA-treated rat. WT-PCLS / FXRKO-PCLS; PubMed: 26482353 BMC Genomics. Histological analysis of liver slices treated with cyclosporin A (CsA). WT-PCLS (a-d) were cultured for 24 and 48 h in the presence of DMSO (a and c) or 40 μM CsA (b and d). FXRKO-PCLS (e-h) were cultured for 24 and 48 h in the presence of DMSO (e and g) or 40 μM CsA (f and h).	30916387 10931158 26482353
Immunofluorescence	Human gingival fibroblast cells; PubMed: 27857765 Dent Res J (Isfahan). Human gingival fibroblast cells were incubated with calcium green 1 AM for 1 h and cyclosporin A (25 μM) and angiotensin II (100 μM) were added and nuclei stained with 4, 6diamidino-2-phenylindole (blue), imaging was done using an immunofluorescence microscopy under x10 (a). Time-dependent calcium intensity was measured (b). CsA: Cyclosporin A; Ang II: Angiotensin II; DAPI: 4, 6-diamidino-2-phenylindole. Human gingival fibroblast cells; PubMed: 27857765 Dent Res J (Isfahan). Live staining was done by incubating the human gingival fibroblast cells with calcium green 1 AM for 1 h following which cyclosporin A and angiotensin II was added and images were taken using confocal microscope under × 20 objectives (a). Histogram represents the mean fluorescence intensity (b). CsA: Cyclosporin A; Ang II: Angiotensin II; HGF: Human gingival fibroblasts. Calcein; PubMed: 23593196 PLoS One. E. XR9576, verapamil, and cyclosporin A enhanced calcein fluorescence in KB-V1 cells. KB-V1 cells treated with the indicated compounds and 1 µM calcein AM were imaged 1 hour later. The phase-contrast and fluorescent images were merged and displayed (size bar = 100 µm). Rhod-Dex / Calcein; PubMed: 20584761 Toxicol Sci. Lack of protection by cyclosporin A against acetaminophen-induced lysosomal breakdown and calcein quenching. Mouse hepatocytes were loaded with rhodamine-dextran and calcein, as described in Figure 6 and treated with acetaminophen (AAP) in the presence of fructose plus glycine and cyclosporin A (CsA, 1μM). cadherin-9 / vimentin; PubMed: 17668045 PLoS One. To induce a transition of renal epithelial cells into a spindle-shaped mesenchymal cell type, the epithelial TK 163 cells were cultured for 48 hours in different concentrations (0, 4.2 and 42 µM) of cyclosporin-A (CsA). EMT could be observed by phase contrast microscopy. Immunofluorescence staining revealed that without CsA no signals for cadherin-9 and only weak signal for vimentin could be observed. Induction of EMT by CsA led to a strong up-regulation of both vimentin and cadherin-9 expression.	27857765 23593196 20584761 17668045

体内研究

Cyclosporin A是一种免疫抑制剂，小鼠，大鼠，和荷兰猪经非肠道给药或者口服给药都有效^[6]，临床上用于器官移植中预防免疫排斥。^[7]

激酶实验：^[3]	- 合并磷酸酶试验: 纯化的牛脑钙调磷酸酶和钙调蛋白是购买的。含纯化酶的反应混合物包含100 nM 钙调磷酸酶，100 nM 钙调蛋白，以及5 μM ³²P-标记磷酸化多肽，60 μl (总体积) 试验缓冲液包含20 mM Tris (pH 8)，100 mM NaCI，6 mM MgCl₂，0.5 mM 二硫苏糖醇，每毫升0.1毫克牛血清白蛋白，以及0.1 mM CaCl₂或5 mM EGTA。含细胞裂解物的反应混合物包含20 μl of未稀释裂解物， 5 μM ³²P-标记的磷酸肽，和40 μl 试验缓冲液。反应混合物包含50 μM 多肽412或413和/或 500 nM冈田酸，一种磷酸酶1和2A的特异性抑制剂; 500 nM 冈田酸足以抑制Ca²⁺-不依赖性磷酸酶，而更高浓度时也会部分抑制Ca²⁺-依赖性的活性。30°C下培育15分钟，加入0.5 ml包含5% 三氯乙酸的100 mM 磷酸钾缓冲液(pH 7.0)终止反应。Dowex阳离子交换色谱分离无机磷酸盐，用闪烁计数测定数量。
细胞实验：^[3]	- 合并 Cell lines: Jurkat细胞(无性繁殖J77) Concentrations: ~100 nM Incubation Time: 1小时 Method: 免疫抑制剂以细胞治疗浓度的1000倍溶于乙醇。细胞(10⁶)悬浮于微量离心管1ml完全培养基中；1 μl乙醇或者Cyclosporin A乙醇溶液加入反应液中，细胞在37°C下培育1小时。细胞在冰浴下用1ml PBS洗两次，在50μl低渗缓冲液中裂解，缓冲液每毫升包含50 mM Tris (pH 7.5); 0.1 mM EGTA; 1 mM EDTA; 0.5 mM二硫苏糖醇; 以及50 微克苯甲基磺酰氯，50 微克胰蛋白酶抑制剂，5微克亮抑酶肽，和5 微克抑肽酶。裂解液用液氮冷冻，再在30°C下融化，循环3次，随后在 4°C下以12,000×g离心10分钟。 (Only for Reference)
动物实验：^[6]	- 合并 Animal Models: 大鼠 Dosages: 45毫克/千克 Administration: 口服 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	100 mg/mL warmed (83.15 mM)
	Water	Insoluble
	Ethanol	''''100 mg/mL warmed
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 2% DMSO+30% PEG 300+5% Tween 80+ddH2O	5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Cyclosporin A (NSC 290193) SDF

分子量	1202.61
化学式	C₆₂H₁₁₁N₁₁O₁₂
CAS号	59865-13-3
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	Cyclosporine A, Cyclosporine, Ciclosporin, CsA

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03865888	Completed	Drug: Cyclosporins\|Drug: Tacrolimus	Dry Eye\|Sjogren Syndrome	Pavly Moawd\|Cairo University	October 30 2018	Phase 3
NCT01762657	Withdrawn	Drug: Oral Cyclosporine and Oral Lansoprazole\|Drug: Placebos	Type 1 Diabetes	Perle Bioscience Inc.	September 2014	Phase 3
NCT02130414	Completed	Drug: Sandimmun® IV\|Drug: CyCol® capsules	Healthy	Sigmoid Pharma	July 2014	Phase 1
NCT01693393	Completed	Drug: Cyclosporine A	Sjögren´s Syndrome	Charite University Berlin Germany	March 2010	Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
What is the difference between S2286 (cyclosporin A) and S1514 (cyclosporin)?
回答：
Cyclosporine is a mixture of Cyclosporine A, derivatives of Cyclosporine A, salts of Cyclosporine A. Cyclosporine A is an especially useful Cyclosporine component.

研究领域

产品类型

定制您的化合物库

Cyclosporin A (NSC 290193)

客户使用Selleck生产的Cyclosporin A (NSC 290193)发表文献50篇：

产品安全说明书

Antineoplastic and Immunosuppressive Antibiotics抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Cyclosporin A (NSC 290193) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-05-17)

技术支持

常见问题及建议解决方法